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Summary 
 
Myasthenia Gravis (MG) is an antibody-mediated T-dependent autoimmune 
disease, involving the neuromuscular junction. Experimental autoimmune 
Myasthenia Gravis (EAMG) is induced in female Lewis rats by immunization with 
Acetylcholine Receptor from Torpedo Californica (TAChR) in Complete Freund‘s 
Adjuvant (CFA). The injection induces the activation of specific Th1 cells in 
response to the antigen of immunization, stimulating the production of anti-TAChR 
antibodies (Abs) that are able to cross-react with self-rat AChR, generating 
specific anti rat AChR Abs, which activate complement system inducing the 
receptor and endplate degradation and damaging the transmission from nerve to 
muscle. Therapeutic strategies for MG include immunosuppressive drugs, that 
exert an aspecific immune dysfunction. These treatments are effective in a large 
amount of patients, however, clinical responses to conventional therapies appear 
ineffective in some patients or the severity of side effects can limit their prolonged 
administration. Thus, new specific autoimmune therapies are needed for treatment 
of unresponsive or intolerant MG patients. Pixantrone (PIX), an aza-
antracenedionic derivate, is a drug with antitumor activity due to its cytotoxic 
effect, via DNA intercalation and topoisomerase II inhibition, linked to its 
cumulative dose. Owing to this mechanism of action, PIX presents also an 
immunosuppressive activity and was recently tested in the EAMG, in which have 
demonstrated to improve both preventive and therapeutic treatments when 
administered at the dose 16.25 mg/Kg q7dx3 for a cumulative dosage of 48.75 
mg/Kg [1].  
In the present study we have focused our attention to the therapeutic treatment of 
EAMG; in particular, the aim of our study has been to evaluate different PIX 
schedules, in order to identify the lowest dosage able to ameliorate ongoing 
EAMG, thus further lowering the risk of toxic effects. 
We first evaluated PIX effect on the in vitro proliferative response of lymphoid 
cells, to determine the pharmacologic properties of the drug in presence of 
different cells subpopulations, characterized by different proliferative responses: 
R97-116 specific T cell line, lymphocytes (LNCs) and splenocytes (SPNs) from 
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R97-116 primed rats, SPNs from HD rats and peripheral blood mononuclear cells 
(PBMCs) from human healthy donors. For this purpose, by dose-response curves 
we demonstrated that PIX (0.1 pM - 1 µM) inhibited lymphoid cell responses in a 
dose dependent manner. Moreover our data demonstrated that a lower 
concentration of PIX was sufficient to inhibit 50% of maximal response of R97-116 
specific T cell line, represented by an homogeneous pool of cells (more than 
90%). In mixed populations, such as LNCs and SPNs isolated from R97-116 
primed rats, composed to 20-40% of antigen-specific cells, or even in SPNs from 
HD rats and PBMCs from healthy human donors, the IC50 for PIX is found to be 
increased. Complete suppression of proliferative response, was achieved with nM 
PIX concentrations for cells in active proliferation (i.e. R97-116 T cell line) and 
raised to µM PIX concentrations in presence of SPNs from HD rats and PBMCs 
from healthy human donors. Our in vitro experiments suggested that PIX efficacy 
is higher for T cells that are able to actively proliferate. 
We also tested in vitro whether PIX (0.1 nM, 1 nM, 10 nM, 10 µM) was able to 
interfere with differentiation of myeloid precursors cells (MPCs), from bone marrow 
of HD rats, in immature dendritic cells. The drug resulted toxic (reduction in cell 
viability ≤ 50%) already at PIX 1 nM and the cell viability was dramatically reduced 
to 0% when the cells were exposed to PIX concentrations 10 nM and 10 µM.  
Then we investigated in vivo PIX efficacy, firstly on TAChR-immunized rats treated 
24 h post immunization (p.i.) with a single dose of PIX (16.25 mg/Kg x1, 8.12 
mg/Kg x1, 4.06 mg/Kg x1) and sacrificed after 10 days. A single dose of PIX was 
able to reduce the number of total live cell count of LNCs from PIX treated rats 
compared to vehicle, accordingly with a decrease of ex vivo TAChR specific T cell 
proliferation (90%). In parallel we evaluated the effect of the drug in physiological 
conditions, administered a single dosage of PIX (16.25 mg/Kg) in HD rats or HD 
rats immunized only with CFA and compared to HD controls, but the drug had no 
effect on the number of total live cells on LNCs. These data demonstrated that 
lower PIX doses were able to modulate selectively the TAChR specific proliferation 
in vivo and allowed us to tested alternative schedules, on the base of previous 
studies [1], in the therapeutic treatments. 
We studied in vivo the effect of long-term treatments with PIX in EAMG rats, 
immunized with TAChR/CFA and treated 4 weeks p.i with PIX, at two cumulative 
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dosage 48.75 mg/Kg (16.25 mg/Kg q14dx3 as positive control, 8.12 mg/Kg q7dx6) 
and 24.36 mg/Kg (4.06 mg/Kg q7dx6, 8.12 mg/Kg q14dx3). Vehicle treated rats 
was administered with a sterile saline solution. In parallel we evaluated the effect 
of a chronic administration of PIX in HD rats (16.25 mg/Kg q14dx3) compared to 
HD controls, but PIX treatments did not affected in vivo the body weight of the HD 
animals and had no effect on the number of total live cells of LNCs. At the end of 
the experiments (11 weeks p.i.) only PIX cumulative dosage 48.75 mg/Kg shown a 
pharmacological effect, modulating clinical signs of EAMG (gain of body weight 
and decrease in the clinical score), affecting the number of total live cells of LNCs 
and decreasing the TAChR specific proliferation in the same organ. Moreover, 
qPCR revealed a reduction in IFNγ mRNA transcription levels in SPNs, 
accordingly with the decrease in anti-Rat Abs titre in the sera of the PIX treated 
rats. On the contrary the cumulative dosage 24.36 mg/Kg resulted ineffective in 
the modulation of classical monitoring parameters of EAMG. Although we 
observed an effect on TAChR specific proliferation of LNCs, these treatments 
resulted ineffective to inhibit the production of IFNγ and, as consequence, of 
pathogenic Anti Rat AChR Abs. We also tested in vivo the chronic toxicity of the 
drug on MPCs and both of treatments at the cumulative dosage 48.75 mg/Kg 
resulted myelotoxic in HD and EAMG rats compared to HD controls, but the 
protocol 8.12 mg/Kg q7dx6 presented a lower toxicity compared to the 16.25 
mg/Kg q14dx3. Thus following the protocol 8.12 mg/Kg q7dx6 we observed major 
efficacy in the disease modulation with fewer myelotoxic effects. Conversely the 
cumulative dosage 24.36 mg/Kg did not interfere on cell viability compared to HD. 
In conclusion we speculated that though both of treatments for the cumulative 
dosage 48.75 mg/Kg were able to improve EAMG, PIX pharmacokinetic profile in 
the schedule 8.12mg/Kg q7dx6 overlaps well with its clearance (8 days), thus 
allowing the achievement of a systemic steady-state, with the consequent 
improvement of the efficacy of this treatment compared to 16.25mg/Kg q14dx3 
schedule. The cumulative dosage of 24.36 mg/Kg instead resulted ineffective to 
modulate EAMG because it didn‘t reach the systemic effective dose in rats. 
On the basis of our results we proposed PIX as promising immunomodulatory 
agent suitable for clinical investigation in MG patients, that present severe form of 
the disease or major contraindications to the classical therapies.  
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Chapter 1 – Introduction 
 
1.1 Immunological tolerance and autoimmunity 
 
A key issue in immunology is to understand how the immune system is able to 
discriminate between self and non-self, inhibiting the autoimmune responses and 
activating the immune responses against foreign antigens, respectively [2].  
The immunological self-tolerance is an active process that controls the 
unresponsiveness to the auto-antigens at central level, by the primary lymphoid 
organs, and in the periphery, by the secondary lymphoid organs [3, 4]. The central 
tolerance occurs in the thymus and leads to the clonal deletion of the auto-reactive 
T cells, representing the main mechanism involved in maintaining the tolerance to 
self-antigens [5].  
T lymphocyte progenitors are produced in bone marrow and migrate to the 
thymus, where they will be selected and matured. Firstly, they are double negative 
thymocytes, then productively rearrange α and β T cell receptor (TCR) chains, 
which are first expressed by cluster of differentiation 4 and 8 (CD4+CD8+) double 
positive thymocytes. These cells are selected by positive and negative selection 
processes. 
Selection processes occur in the thymus, due to the capability and the affinity level 
of immature thymocytes to recognize and bind self-antigens, processed and 
presented by major histocompatibility complex (MHC) molecules on thymic antigen 
presenting cells (APCs). CD4+CD8+ thymocytes are positively selected, and 
rescued from programmed cell death, due to low-affinity interactions between their 
rearranged TCR and the self MHC molecules on thymic epithelial cells in the 
thymic cortex. If the MHC molecules belong to the class I or the class II, double 
positive thymocytes will lose the expression of CD4 or CD8 molecules, 
respectively, and they will give rise to single positive thymocytes (CD8+ or CD4+). 
Instead, the negative selection results in the immature thymocytes deletion via 
apoptosis, due to high-affinity interactions between their rearranged TCR and the 
self-antigens presented by MHC molecules on APCs in the thymic medulla or in 
the corticomedullary junction. The thymic negative selection is the main 
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mechanism of self-tolerance: failures in this process can lead to autoimmune 
diseases.  
The selected thymocytes further undergo maturation, leave the thymus and 
migrate to the peripheral lymphoid organs [6-9]. However, auto-reactive T cells 
may escape the thymic clonal deletion and recognize peripheral tissue antigens, 
effecting autoimmunity. Despite these escaped cells are normally present in all 
individuals, autoimmune diseases affect only about 5% of the population, 
suggesting that peripheral self-tolerance mechanisms must exist to control 
potential pathogenic T cells [10]. 
The peripheral tolerance is a continuous process that occurs when mature 
lymphocytes, escaped from negative selection during ontogeny, encounter self-
antigens in secondary lymphoid organs. This process is mainly controlled by 
specific regulatory T (Tr) cell subsets and includes different mechanisms as 
ignorance, deletion by apoptosis, anergy induction and active suppression [4, 5]. 
Several types of Tr cells play the role of immunosurveillance: from the CD4+ 
repertoire, naturally occurring CD4+CD25+ regulatory T (Treg) cells and induced 
CD4+ Tr cells, including Tr1 and T helper 3 (Th3) cells; from other cell subsets, 
naturally occurring regulatory NKT cells and CD8+ regulatory T cells [8]. 
1.2 Myasthenia Gravis 
 
Myasthenia Gravis (MG) is a relatively rare neuromuscular disease, characterized 
by the loss of nicotinic acetylcholine receptors (AChRs), key molecules for the 
neuromuscular transmission and the consequent muscle contraction. The loss of 
AChRs leads to muscle weakness and fatigability, the main symptoms of the 
pathology [11]. In the 1980s, several immunologists studied the potential 
implication of antibodies (Abs) in MG and found in the plasma of myasthenic 
patients anti-AChR-specific Abs (in particular polyclonal immunoglobulin G, 
predominantly belonging to IgG1 and IgG3 subtypes), reactive to different epitopes 
on the surface of AChRs [12]. More than 85% of MG patients develop antibodies 
against AChRs [13].  
Acquired MG is an uncommon disorder, although prevalence has increased over 
time and is recently estimated around 50-125 cases per million [14]; this correlates 
with an improvement in diagnosis techniques and with a major life span. The 
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annual incidence rate widely varies from 1.7 to 10.4 per million, depending on the 
location of the studies [15, 16].  
The disease onset is influenced by both sex and age: the incidence is higher in 
women than in men, (3:1 ratio) during early adulthood (age <40 years), is roughly 
equal during puberty and after 40 years of age, instead is higher in men than in 
women after 50 years of age [17]. Childhood MG is uncommon in Europe and 
North America, comprising 10–15% of cases [15]; it is much more common in 
Asia, such as in China, where up to 50% of myasthenic patients develop the 
disease before 15 years of age, mainly with the typical symptoms of ocular MG 
[18]. 
1.2.1 MG subtypes 
 
Several Myasthenia Gravis subtypes can be identified on the basis of differences 
in clinical presentation, age at onset, autoantibody profile, and presence or 
absence of thymic pathology. 
Patients with generalized MG can be distinguished for early- and late-onset 
disease, usually defined as beginning before or after 40 years of age, respectively 
[19]. Early-onset patients are usually females, with anti-AChR antibodies and 
enlarged hyperplastic thymus glands. They may develop other organ-specific 
autoantibodies and be affected by other autoimmune pathologies, most commonly 
autoimmune thyroid diseases [20]. Late-onset patients are usually males, with 
normal thymic histology or thymic atrophy at last. They can be also affected by 
ocular symptoms, typically develop a more severe disease than early-onset MG 
patients and rarely go into spontaneous remissions [21]. Furthermore, these 
patients usually present antibodies reactive to striated muscle proteins, such as 
titin and ryanodine receptor (RyR) [22]. The presence of anti-RyR antibodies, is 
associated with severe, generalized and oropharyngeal weakness and frequent 
myasthenic attack [23].  
About 10–15% of MG patients are affected by thymic epithelial tumor, known as 
thymoma,. present in men and women with equal incidence; it can occur at any 
age, with an onset peak at 50 years of age [24]. Clinical manifestations, commonly 
characterized by progressive generalized and oropharyngeal weakness, result 
more severe than in early-onset MG patients, without thymoma.  
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Myasthenic patients with thymoma present a high titer of anti-AChR Abs and 
usually develop antibodies against titin and ryanodine receptor [25]. In these 
patients, the thymectomy often completely and permanently removes the tumor, 
but myasthenic symptoms usually persist and require chronic immunotherapy [16].  
Approximately 15% of patients with generalized MG do not show anti-AChR Abs, 
while in 40% of these, antibodies directed to Muscle Specific Kinase (MuSK), a 
postsynaptic neuromuscular junction (NMJ) protein, are detected [26]. MuSK-
positive MG onset appears earlier and patients are predominantly females [27]. 
Subjects with anti-MuSK antibodies can show symptoms similar to anti-AChR-
positive MG patients, but commonly develop atypical clinical features, such as 
selective facial, bulbar, neck, and respiratory muscle weakness and marked 
muscle atrophy, occasionally with relative sparing of ocular muscles [27]. In anti-
MuSK-positive MG, respiratory attacks are more common than in generalized anti-
AChR-positive disease, while thymic alterations are usually absent [28].  
MG patients without both anti-AChR and anti-MuSK Abs (seronegative MG 
patients) show heterogeneous clinical signs and can develop purely ocular, mild 
generalized, or severe generalized disease. Seronegative patients are essentially 
indistinguishable from patients with anti-AChR-positive MG for clinical features, 
pharmacological treatments response and even thymic abnormalities in some 
cases [29].  
When myasthenic symptoms involve exclusively ocular muscles, the disease is 
defined ocular Myasthenia Gravis, and represents 17% of all MG subtypes in white 
populations [17]. Ocular MG seems to be more common in Asia (up to 58% of all 
myasthenic patients), with prevalence in children [18]. In 90% of cases the disease 
do not generalize, if the muscular weakness remains confined to the ocular 
muscles for at least 2 years [17]. Up to 50% of ocular MG patients develop anti-
AChR Abs, but a high antibody titer do not necessarily predict a potential 
generalization of the disease [30]. Anti-MuSK antibodies are rarely detected in 
ocular MG [31]. 
Transient neonatal Myasthenia Gravis is characterized by muscle weakness, due 
to trans-placental transfer of maternal pathogenic auto-antibodies, and occurs in 
approximately 10–15% of infants born to mothers with MG [32]. Myasthenic 
symptoms usually develop a few hours after birth, but may be delayed for 24 hours 
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or longer. A prophylactic treatment with plasma-exchange or steroids or both of 
them can be considered in a woman with a previously affected child, as the risk of 
recurrent transient neonatal MG is high [16]. 
1.2.2 Immunopathogenesis  
 
MG is a T-cell dependent antibody-mediated autoimmune neuromuscular disease 
[11], in which AChR is the main autoantigen and the postsynaptic membrane of 
the NMJ is the target for antibody-induced damage. In about 85% of patients, MG 
is caused by pathogenic autoantibodies directed to nicotinic AChR on muscle 
cells. The amount of Abs in patients serum is variable, but the antibody titer does 
not correlate with the clinical severity of MG [13].  
 
Structure and function of the NMJ 
The neuromuscular junction is formed by the nerve terminals of α–motor neurons 
that originate from the ventral horns of the spinal cord and brain stem (Figure 1.1). 
The myelinated axons reach the muscles through peripheral nerves and divide into 
branches to innervate many individual muscular fibers.  
As each branch approaches its target fiber, it loses the myelin sheath and further 
divides into several pre-synaptic bottons, containing acetylcholine (ACh)-loaded 
synaptic vesicles and interacts with the surface of the muscle fiber at the NMJ 
(Figure 1.1). The pre-synaptic botton and the muscle surface are separated by the 
synaptic cleft, a 20 nm–thick space containing acetylcholinesterase (AChE), 
enzyme with hydrolytic activity that degrades the ACh, and other proteins, 
including proteoglycans involved in stabilizing the NMJ structure.  
The post-synaptic membrane presents characteristic deep folds, on the top of 
which the ACh-receptors are densely packed (about 12,000 molecules per μm2) in 
highly ordered hexagonal lattices of molecules. Muscle AChRs are 
transmembrane proteins characterized by 5 subunits: 2 identical α subunits, 
constituting the important structural elements for the ACh-binding sites, and 3 
homologous subunits, β, γ (or ε), and δ. Embryonic muscle expresses AChRs 
formed by α, β, γ, and δ subunits; after innervation, the adult AChR isoform is 
generated by the substitution of the γ subunit with the homologous ε subunit 
(Figure 1.2) [33]. A large amount of the antibodies in the sera of MG patients binds 
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to the main immunogenic region (MIR), localized between residues 67 and 76 of 
both α subunits of the receptor (Figure 1.2).  
 
Figure 1.1  Structure of the NMJ, Conti-Fine et al., 2006  [33].  
 
In addition, many patients‘ Abs bind to the fetal-specific γ subunit. In some cases, 
these antibodies inhibit the function of the AChR, and can cross the placenta in 
pregnant mothers, causing fetal muscle paralysis and severe, often fatal, 
deformities [11].  
α-Bungarotoxin (α-BTX), a component of the venom of the snake Bungarus 
multicinctus, it is the most common antagonist of AChR and interacts irreversibly 
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and competitively with the ACh-binding sites, causing paralysis, respiratory failure 
and death (Figure 1.2). 
When the nerve action potential reaches the synaptic botton, the depolarization 
opens voltage-gated Ca2+ channels on the pre-synaptic membrane. This Ca2+ 
influx triggers fusion between the membrane of the synaptic vesicles and the pre-
synaptic membrane, allowing ACh release. The ACh diffuses into the synaptic 
cleft, reaches and binds its receptor, triggering the opening of cation channel and 
the consequent influx of Na+ into the muscle cell. The resulting endplate potential 
(EPP) activates voltage-gated Na+ channels, leading to further influx of Na+ and 
spreading the action potential along the muscle fiber.  
 
 
Figure 1.2  Fetal and adult forms of the acetylcholine receptor. (a) The 
acetylcholine receptor is a pentameric membrane protein. (b) Each of the subunits 
consists of an extracellular domain, four transmembrane regions and a cytoplasmic 
domain. The receptor consists of (α)2, β, γ and δ subunits in the fetal form (c), and (α)2, 
β, δ and ε subunits in the adult form (d), Vincent, 2002 [11]. 
 
The post-synaptic transmembrane protein, MuSK (Figure 1.1), is the autoantigen 
in some MG patients [34]. Its expression in both developing and mature muscles is 
similar to that of AChR. In mature muscle, MuSK is present prominently only at the 
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NMJ, where seems to be part of the agrin receptor. Agrin is a protein synthesized 
by motor neurons and secreted into the synaptic basal lamina. The signaling 
induced by agrin/MuSK interaction triggers and maintains rapsyn-dependent 
clustering of AChRs and other post-synaptic proteins [35]. 
Rapsyn, peripheral protein exposed on the cytoplasmic side of the post-synaptic 
membrane, is necessary for clustering of AChRs. Rapsyn and AChR are 
physically associated and present in equimolar concentrations at the NMJ. Rapsyn 
also causes clustering of other NMJ proteins, including MuSK. Mice, lacking agrin 
or MuSK, fail to form NMJs and die at birth for profound muscle weakness; their 
AChR and other synaptic proteins are uniformly distributed along the muscle fibers 
[36].  
The quantal content of an impulse, the conduction properties and density of post-
synaptic AChR, and the activity of AChE in the synaptic cleft contribute to the EPP 
[37]. A reduction in the number or activity of the AChR molecules at the NMJ 
decreases the EPP, despite may still be adequate at rest; however, when the 
quantal release of ACh is reduced after repetitive activity, the EPP may fall below 
the threshold needed to trigger the action potential. NMJ properties vary among 
muscles and may influence muscle susceptibility to MG [37].  
 
Effector mechanisms of anti-AChR Abs  
Anti-AChR Abs affect neuromuscular transmission by at least 3 mechanisms: (a) 
binding and activating the complement cascade at the NMJ; (b) accelerating the 
degradation of AChR molecules cross-linked by Abs (a process known as 
antigenic modulation); and (c) blocking functional AChR (Figure 1.3). 
The NMJ of MG patients contains activation fragments of complement component 
3 (C3), the terminal and lytic complement component 9 (C9), and the membrane 
attack complex (MAC) [38]. Different evidences suggest that the complement 
activation at the NMJ may be the primary cause of AChR loss and neuromuscular 
transmission failure (Figure 1.3 - a). 
Studies on MG animal models indicate that the complement depletion protects 
animals from Experimental Autoimmune MG (EAMG) [39]. For instance, the 
administration of Abs blocking complement component 6 (anti-C6) [40] or a 
complement inhibitor (soluble CR1) [41] protects rodents from EAMG; moreover, 
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mice with a reduced complement function, due to a genetic deficit of complement 
components, are resistant or less susceptible to EAMG induction than wild type 
mice [42]. Karachunski and colleagues studied IL-12–deficient mice, characterized 
by a poorly Abs-generated complement-fixing [43], and demonstrated that IL-12 
Knock-Out (KO) mice developed minimal myasthenic symptoms after AChR 
immunization in spite of elevated anti-AChR Abs synthesis; the NMJs in these 
mice contained antibodies but not complement, suggesting that, anti-AChR Abs 
not activate the complement, do not compromise neuromuscular transmission [43]. 
Cells are protected from activation of autologous complement by intrinsic 
complement regulators. These include the decay-accelerating factor (DAF or 
CD55), the membrane co-factor protein (MCP or CD46), and the membrane 
inhibitor of reactive lysis (MIRL or CD59) [44-46].  
 
Figure 1.3. Effector mechanisms of anti-AChR Abs. (a) Ab binding to the AChR activates the 
complement cascade, resulting in the formation of membrane attack complex (MAC) and 
localized destruction of the postsynaptic NMJ membrane. (b) Abs cross-link AChR molecules 
on the NMJ postsynaptic membrane, causing endocytosis of the cross-linked AChR molecules 
and their degradation (antigenic modulation). (c) Ab binding the ACh-binding sites of the 
AChR causes functional block of the AChR by interfering with binding of ACh released at the 
NMJ. Conti-Fine et al., 2006 [33]. 
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Antigenic modulation is the ability of an Ab to cross-link two antigen molecules, 
triggering a cellular signal that causes accelerated endocytosis and degradation of 
the cross-linked molecules (Figure 1.3 - b). IgG from MG patients causes antigenic 
modulation of muscle AChRs [47] and this property can be applied as a diagnostic 
test [48]. if accelerated degradation is not compensated by increased synthesis 
[48], reduction of the available AChR molecules at the NMJ and myasthenic 
symptoms will be observed. This feature can be employed as a diagnostic test for 
MG [48], although, not all anti-AChR Abs cause antigenic modulation: all IgG 
present two antigen-binding sites, but the epitope location on the AChR surface 
may inhibits the cross-reaction of an antibody with a second molecule [49].  
Functional AChR block, due to the interaction between anti-receptor Abs and ACh-
binding site, (Figure 1.3 - c) is an uncommon pathogenic mechanism in MG, yet it 
may be clinically important. More studies show that the presence of Abs to the 
ACh-binding site causes acute, severe muscle weakness in rodents without either 
inflammation or necrosis at the NMJ [50]. Many MG patients develop a low amount 
of anti-AChR Abs recognizing the ACh-binding site [51]; however, these antibodies 
may be able to block the receptor function and trigger the acute myasthenic crises 
[16]. 
 
Role of CD4+ T cell subtypes and cytokines in MG and EAMG  
Differentiated CD4+ T cells are classified into different subtypes based on the 
cytokines they produce and secrete. T helper 1 (Th1) and T helper 2 (Th2) cells 
show different and opposing functions [52] (Figure 1.4). Th1 cells secrete pro-
inflammatory cytokines, such as interleukin-2 (IL-2), interferon γ (IFN-γ), and tumor 
necrosis factor-α (TNF-α), important in cell-mediated immune responses. Th2 cells 
secrete anti-inflammatory cytokines, such as interleukin-4 (IL-4), interleukin-6 (IL-
6), and interleukin-10 (IL-10), important in humoral immune responses. Moreover, 
IL-4 stimulates the differentiation of T helper 3 (Th3) cells, which are involved in 
immunosuppressive mechanisms, secreting transforming growth factor-β (TGF-β) 
[53].  
Both Th1 and Th2 cytokines may induce Abs production by B cells. However, they 
promote the synthesis of different immunoglobulin (Ig) types. Th1 cells induce IgG 
subclasses that efficiently bind and activate the complement, whereas Th2 cells 
 18 
 
induce Ig isotypes and IgG subclasses (IgG4 and IgE) that poorly or not at all fix 
the complement. MG patients present numerous AChR-specific Th1 cells in blood, 
that recognize many AChR epitopes and induce synthesis of pathogenic auto-Abs 
interacting with B cells [54].  
MG patients present also AChR-specific Th2 and Th3 cells in blood [55]. Several 
studies show that Th1 cells and their cytokines are needed for EAMG 
development, probably for their role in inducing production of complement-binding 
pathogenic anti-AChR Abs [43, 56]. Moreover, experimental studies on EAMG 
demonstrate that estrogens promote the disease development in mice increasing 
interleukin-12 (IL-12) production by AChR-specific Th1 cells, suggesting that 
estrogens may mediate sex differences in autoimmunity with a Th1-driven 
mechanism (Figure 1.4) [57]. 
 
Figure 1.4. Cytokine network and cells involved in the pathogenesis and immune regulation of MG. 
Th1 cytokines stimulate production of IgG subclasses that bind and activate complement, whereas 
Th2 cytokines stimulate the production of Ig classes and IgG subclasses that do not involved in MG. 
The Th2 cytokine IL-4 is also a differentiation factor for Th3 cells, immunosuppressive cells that 
secrete TGF-β. The Th1 cytokine IFN-γ stimulates expression of MHC class II molecules on the 
muscle cell membrane, thus facilitating presentation of muscle AChR. The IL-18 secreted by APCs 
favors the differentiation of Th1 cells both directly and indirectly through the action of NK cells. CD1-
d–restricted NKT cells can activate Tregs, thereby inhibiting autoimmune processes, Conti-Fine et al., 
2006 [33]. 
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Pro-inflammatory Th1 cytokines induce expression of MHC class II molecules in 
muscle, promoting the presentation of AChR epitopes and further the expansion of 
activated AChR-specific CD4+ T cells [58]. Increased IFN-γ production may 
explain the increased expression of IFN-γ–induced chemokines and monokines 
and their receptors in muscle, thymus, and lymph nodes in MG patients. A 
decrease in chemokine expression correlates with a decrease in severity of MG 
symptoms [59].  
Studies performed in EAMG animal models show that AChR-specific Th2 cells 
present complex and contrasting roles: they can be protective [60, 61], but the 
cytokines interleukin-5 (IL-5), IL-6, and IL-10 are also able to promote EAMG 
development [62, 63].  
Other helper T cell subtypes may perform a role in MG. CD4+ T cells, that express 
the CD25 marker and the transcription factor forkhead box P3 (Foxp3) on their 
surface, are known as Treg cells and are important in maintaining self-tolerance 
(Figure 1.4). Regulatory T cells in MG patients may be functionally impaired [64]. 
and the number of circulating Tregs has been shown to increase after 
thymectomy, according to a symptom improvement [65].  
Also Natural Killer (NK) and NKT cells show a role in restoring self-tolerance in 
MG. NKT cells and Tregs may cooperate in regulating the anti-AChR response. In 
AChR-immunized mice, the activation of NKT cells, by a synthetic glycolipid 
agonist, inhibits EAMG development; these therapeutic effects are likely mediated 
by the increase in number and modulatory functions of induced Tr cells [66]. NK 
cells can influence the development of EAMG, and possibly MG: indeed, in mice, 
NK cells are necessary for EAMG induction, promoting IFN-γ secretion and Th1 
cells sensitization [67].  
Interleukin-18 (IL-18), secreted by APCs is an important growth and differentiation 
factor for both NK and Th1 cells, especially in cooperation with IL-12 [56]. Thus, 
IL-18 may be important in the pathogenesis of MG and its experimental model. 
Indeed, IL-18–deficient mice are resistant to EAMG, as the pharmacologic 
blockade of IL-18 suppresses the disease [56, 67]. Moreover, MG patients show 
increased serum levels of this cytokine, which tend to decrease in parallel with 
clinical improvement, thus supporting a role for IL-18 in human disease [68]. 
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Other autoantigens in MG  
Up to 15% of MG patients do not develop anti-AChR Abs and are consequently 
known as seronegative patients [29]. In 40% of them, [69] antibodies against 
MuSK are detected. Anti-MuSK-positive MG patients never show anti-AChR Abs 
[69]. The agrin/MuSK signaling pathway likely maintains the structural and 
functional integrity of the post-synaptic NMJ apparatus also in adult muscle. IgG 
from anti-MuSK-positive MG patients disrupt AChR aggregation in myotubes from 
MuSK-immunized animals and block agrin-induced AChR clustering [34, 70]. 
Several studies confirm the effect of anti-MuSK Abs on the agrin-dependent 
maintenance of AChR clusters at the NMJ, leading to reduced AChR number [70]. 
Complement-mediated damage may also be responsible for loss of AChRs and 
NMJ impairment. However, some MG patients with anti-MuSK Abs do not present 
AChR loss at the NMJ [71], because they predominantly belong to IgG4 subtype 
and do not efficiently bind the complement [26]. Moreover, some studies show that 
anti-MuSK Abs do not cause significant AChR loss, complement deposition, or 
morphologic damage at the NMJ [71].  
Anti-MuSK Abs may perform other pathogenic mechanisms; in a recent study 
effects of sera from anti-MuSK-positive MG patients on muscle cell cultures has 
been investigated [72]. Authors shown that some sera inhibit cell proliferation, by 
causing cell cycle arrest, and down-regulate the expression of AChR subunits, 
rapsyn, and other muscle proteins [72].  
Some anti-AChR/MuSK-negative patients may develop a plasma factor that 
activates an alternative pathway in the muscle, resulting in phosphorylation and 
inactivation of the AChR [73].  
MG patients may also synthesize Abs against non-muscle-specific proteins, such 
as myofibrillar proteins [22]; some of those antibodies, especially anti-myosin Abs 
and anti-fast troponin Abs, may cross-react with the AChR [74]. Moreover, MG 
patients with thymoma can develop Abs against titin [75] and ryanodine receptor 
[76]. 
 
The role of the thymus  
The role of the thymus in MG is still unknown, even if its involvement has been 
reported since the beginning of the 1900s [77]. Marked pathological alterations of 
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thymus occur in over 80% of anti-AChR-positive patients [11]: thymic hyperplasia 
is observed in 50–60% of seropositive cases and in a variable proportion of 
seronegative cases, thymoma is present in 10–15% of cases [78]. A hyperplastic 
thymus typically contains B-cell infiltrates that can organize into ectopic germinal 
centers (GCs - structures specialized for the expansion and affinity maturation of 
B-cell clones), forming B-cell follicles (follicular hyperplasia) or being distributed 
throughout thymic medulla (diffuse hyperplasia, also known as thymitis) [78]. 10–
20% of anti-AChR-positive patients show an atrophic thymus very similar to that of 
age-matched controls for the amount of adipose tissue and epithelial space; it is 
characterized by the presence of infiltrating B cells, being indicative of thymic 
hyperplasia and immune activation. The thymus of anti-AChR-positive MG patients 
contains all the components required to initiate and sustain the autoimmune 
response: autoantigen, expressed on muscle-like myoid cells [79] and thymic 
epithelial cells (TECs) [80], professional APCs [81], AChR-specific T cells [82], and 
plasma cells producing anti-AChR antibodies [83].  
Furthermore, in 2003 Levinson and colleagues developed a new model of intra-
thymic inflammation and speculated a feasible mechanism explaining thymus 
involvement. The hypothesis, still to be tested, was that an inflammatory reaction 
against an unrelated antigen within the thymic medulla might promote the entry of 
peripheral AChR α-reactive CD4+ T cells that escaped central deletion (Figure 
1.5) [84].  
 
Figure 1.5 Intra-thymic pathogenesis of MG, Levison et al., 2003 [84]. 
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These cells entered the thymic medullary compartment, where they encountered 
AChR α expressed on APCs. The concomitant intra-thymic inflammatory reaction 
created a milieu that favored the activation of these cells, with up-regulation of 
MHC class II and co-stimulatory molecules on APCs and, maybe, with up-
regulation of AChR expression. The presentation of AChR α epitopes to migrated-
thymus CD4+ T cells might lead to Th1 cell activation, increased local stimulation 
of AChR α-reactive B cells/plasmacells with consequent secretion of anti-AChR 
Abs and production of germinal centers (GCs), finally promoting MG development 
[84]. 
Several evidences demonstrate the association between MG and thymic tumor; 
however, although the thymectomy benefits younger MG patients with thymoma, 
no clinical improvement are often observed, requiring additional 
immunosuppressive therapies. MG patients with thymoma can develop also anti-
titin and anti-ryanodine receptor antibodies [85]. 
 
Molecular mimicry 
Some studies suggest that environmental factors are involved in the etiology of 
MG [86, 87]. Among them, viral infections are suspected to play a role in the 
development of autoimmunity by mechanisms including general activation of the 
host immune system and molecular mimicry [88]. The pathogens act as promoters 
of an auto-sensitization process mainly by initiating an innate immune response 
that stimulates inflammation and activates the host immune system [88]. 
Furthermore, evidences of chronic thymic inflammation in most MG patients [89] 
makes plausible the hypothesis that persistent viruses or other microbial agents 
may contribute to intra-thymic pathological mechanisms of the disease. The high 
affinity and specificity of anti-AChR antibodies in MG patients [12] imply that the 
human AChR is the antigen, even if another antibody or a microbial antigen that 
contains epitopes mimicking the AChR, could be involved in the etiology of MG. 
Indeed, thymic expression of antigenic fragments, or some idiotypic perturbation or 
microbial trigger, might initiate the production of low-affinity antibodies specific for 
AChR, which ‗spread‘ to induce the high-affinity and heterogeneous antibodies 
that cause disease symptoms [11]. 
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Cavalcante and colleagues have found indication about a viral contribution to 
onset or maintenance of the intra-thymic autoimmune response in MG patients 
[86, 87, 90]. In these studies, they have discovered evidences of chronic poliovirus 
infection in the thymus of some MG patients, suggesting that persisting viruses, 
which stimulate innate immune responses and chronic inflammation, may be 
responsible for immunological alterations and auto-sensitization in this organ [86, 
90].  
 
Figure 1.6 Proposed model of virus-induced autoimmunity in MG. A ―danger signal‖ (e.g., pathogen infection) 
stimulates Toll-like receptor- (TLR-) mediated innate immune responses (a), whose dysregulated or persistent 
activation leads to the chronic inflammation characteristic of MG thymus (b). The chronically established 
thymic inflammatory state (c), characterized by overexpression of proinflammatory cytokines (e.g., IL-6, IL-10), 
type I and II IFNs, and T- and B-lymphocyte-attracting chemokines (e.g., CXCR3, RANTES, CXCL13, 
CCL21), is essential, in the context of a genetically predisposing background, for the establishment of 
mechanisms (d) contributing to T-cell autosensitization, including presentation or cross-presentation of ―self-
epitopes‖ by TECs or myoid cells expressing the autoantigen; upregulation of MHC genes; activation of APCs; 
as well as the constant priming of autoreactive T cells, which in turn promote autoimmune response by 
autoreactive B cells (e). B cell attractants CXCL13 and CCL21 recruit circulating B cells to thymus, including 
those harboring EBV (a‘). EBV infection itself contributes to thymic inflammation (b‘). EBV reactivation, 
influenced by the inflammatory state (c‘), results in EBV propagation to uninfected B cells (d‘) including AChR-
specific B cells (e‘). The chronically established inflammation and EBV infection promote the maintenance 
within the thymus of the autoimmune response (f), which may be thus perpetuated in periphery (g), 
Cavalcante et al., 2011 [87]. 
Moreover, they have identified an abnormal accumulation of Epstein-Barr virus- 
(EBV-) infected B cells and plasma cells in MG thymuses, but not in normal control 
[86]. Since EBV has the unique ability to disrupt B-cell regulatory check-points and 
 24 
 
to interfere with the B-cell differentiation program [91], their findings have 
suggested that EBV infection may contribute to chronic B-cell activation and 
persistent autoimmune response in this organ in MG patients [86].  
Finally, the authors have proposed a mechanism to explain the etiology of MG: the 
inflammation, triggered by an endogenous or exogenous (e.g., microbial infection) 
danger signal, might drive the colonization of thymus by EBV-harbouring B cells 
and the subsequent EBV re-activation (Figure 1.6). Persistent EBV infection itself 
might contribute to maintain a chronically inflamed thymic microenvironment, 
where the virus might promote disruption of B-cell tolerance check-points, resulting 
in expansion of auto-reactive B-cell clones (Figure 1.6). EBV infection thus could 
explain how the autoimmune response has appeared perpetuated in MG thymus, 
for the potential capability of the virus to immortalize B cells producing AChR 
antibodies [87]. 
 
Immunogenetics in MG 
The biological and clinical heterogeneity of autoimmune MG seems to correlate 
with genetic markers, most notably the Human Leukocyte Antigen (HLA) genes 
[92]. The HLA genes encode for the MHC region, i.e. the antigen-presenting 
proteins on the cell surface. The most intensely studied HLA genes are the nine 
so-called ―classical MHC genes‖: HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, 
HLA-DQA1, HLA-DQB1, HLA-DRA, and HLA-DRB1. In humans, the MHC is 
divided into three regions: Class I, II, and III. The A, B, C, E, F, and G genes 
belong to MHC class I, whereas the six D genes belong to class II. MHC genes 
are expressed in co-dominant fashion: the alleles (variants) inherited from both 
progenitors are expressed in equivalent way: 
 each person inherits a set of genes, belonged to Class I locus (named in 
humans HLA-A, HLA-B and HLA-C) from each progenitor, thus any cell in each 
individual can express 6 different types of MHC-I molecules; 
 in the Class II locus, each person inherits a couple of genes HLA-DP (DPA1 
and DPA2, encoding α and β chains), a couple of genes HLA-DQ (DQA1 and 
DQA2, encoding α and β chains), one gene HLA-DRα (DRA1) and one or two 
genes HLA-DRβ (DRB1 and DRB3, -4 or -5). Thus, a heterozygous individual 
can inherit 6 or 8 Class II alleles, three or four from each progenitor. 
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The set of alleles, present in each chromosome, is called MHC haplotype. In 
humans, each HLA allele is identified by a number (e.g. HLA-A2, HLA-B5, HLA-
DR3). Each heterozygous individual will have two MHC haplotypes, one for each 
chromosome (one of paternal origin and the other of maternal origin). 
The most consistent finding in MG patients is the association of HLA-DR3 and B8 
alleles with early-onset MG and thymic hyperplasia [92]. Late-onset MG is less 
strongly associated with HLA-DR2 and B7 [93]. HLA-DR3 and DR7 seem to have 
opposing effects on MG phenotype: DR3 show a positive association with early-
onset MG and a negative association with late-onset anti-titin-positive MG; DR7 
show opposite effects [94]. No clear genetic links have been found for MG with 
thymoma, but patients with particular genetic profiles present a higher risk of 
developing MG [95].  
Recently, an association with DR14-DQ5 has been reported in patients with anti-
MuSK antibodies [96]. Anti-MuSK-positive MG is less frequent in some ethnic 
groups or geographical locations (e.g. China, Netherlands), suggesting genetic as 
well as possible environmental influences [97].  
It has been also demonstrates that several non-HLA genes, such as the protein 
tyrosine phosphatase, non-receptor type 22 (PTPN22 - lymphoid) and the 
cholinergic receptor nicotinic alpha polypeptide 1 (CHRNA1 - muscle), are 
associated with MG [93]; some of these genes are involved in other autoimmune 
diseases, suggesting a non-specific susceptibility to autoimmunity. An exception is 
represented by CHRNA1 gene, which encodes for the α-subunit of the AChR and 
might provide MG-specific pathogenetic clues [16]. 
1.2.3 Clinical Symptoms 
 
The main MG clinical symptoms are muscular weakness and fatigability, usually 
involving specifically susceptible muscle groups. Patients often show weakness 
fluctuating from day to day or even from hour to hour, worsening with activity, and 
improving with rest. Patients can be affected by varying degrees of ptosis, 
diplopia, dysarthria, dysphagia, dyspnea, facial weakness, or fatigable limb or axial 
weakness [16].  
Ocular weakness, as fluctuating ptosis and/or diplopia, is most commonly the first 
presentation of MG, occurring in approximately 85% of patients [17]. Disease 
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progression to generalized weakness usually occurs within 2 years of the onset 
and weakness of facial muscles is common [16].  
Bulbar weakness, characterized by painless, dysphagia, dysarthria, or chewing 
difficulties, is the first symptom in up to 15% of patients [98]. Weakness involving 
respiratory muscles rarely occurs, but it can be life-threatening and need an 
immediate therapeutic action [16].  
1.2.4 Diagnosis 
 
Available tests, applied to confirm the clinical diagnosis of MG, include bedside 
tests, such as the edrophonium or ice-pack test, electrophysiological analysis, 
measure of the concentrations of serum autoantibodies and scan tests [16]. 
 
Bedside tests 
Edrophonium chloride is a short-acting AChE inhibitor that increases availability of 
ACh and thus prolongs its action at the NMJ, increasing the amplitude and 
duration of the EPP. The test consists in edrophonium intravenous administration 
and observation of the patient for an immediate improvement in muscle strength 
[99]. Some studies indicate that its sensitivity in the diagnosis of MG is 71.5–95% 
for generalized disease [99], but today this test is not commonly used.  
The ice-pack test is a non-pharmacological test that is performed by applying an 
ice pack over the eye for 2–5 minutes and assessing for an improvement in ptosis 
[100]. Its use should be mainly considered in patients with ptosis, in whom the 
edrophonium test is contraindicated. 
 
Electrophysiological tests 
Repetitive nerve stimulation is the most commonly employed electrophysiological 
test for evaluating the neuromuscular transmission. In disorders of the NMJ, low 
rates of nerve stimulation (2–5 Hz) produce a progressive decrement in amplitude 
of the compound muscle action potential. The result of this test is abnormal in 
approximately 75% of patients with generalized MG (<50% of ocular MG) [100]. 
The single-fiber electromyography test (SFEMG) measures the neuromuscular 
jitter resulted from fluctuations in the time taken for the EPP to reach the threshold 
for muscle fiber action potential, generated from an individual muscle fiber. 
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SFEMG reveals abnormal jitter in 95–99% of MG patients [101]. The jitter can also 
be assessed by using conventional electromyography electrodes, less sensitive 
than SFEMG [102]. Although highly sensitive, increased jitter is not specific for 
NMJ disease, but it might be found in nerve or even muscle disease [100].  
 
Immunological tests 
The immunological tests are most commonly applied for MG diagnosis. They 
measure the amount of serum antibody that bind muscle AChR, as detected by 
radio-immuno assay with 125I-labelled α-Bungarotoxin [13]. The presence of anti-
AChR Abs is estimated around 85% for generalized MG and 50% for ocular MG 
[13].  Anti-AChR antibody titer widely varies among patients with similar muscular 
weakness, thus they can not predict the severity of disease. Patients might result 
falsely seronegative if they are following an immunosuppression therapy or if the 
test is performed too early in the disease [103].  
Other immunological assays measure in patients‘ sera anti-striated muscle 
(striational) Abs recognizing muscle cytoplasmic proteins (titin, myosin, actin, and 
ryanodine receptors). Anti-striational Abs are detected in 75–85% of MG patients 
with thymoma and in some subjects affect by the tumor without MG [22, 104]. 
Thus, the presence of anti-striational Abs in early-onset MG raises the suspicion of 
thymoma. Nevertheless, antibodies reactive against titin and other anti-striational 
Abs are also found in up to 50% of patients with late-onset MG, without thymoma; 
therefore these Abs cannot be considered predictors of the tumor in patients over 
50 years aged [21, 105].  
Patients with anti-AChR-negative generalized MG are tested for the presence of 
anti-MuSK Abs, found in approximately 40% of them [26]. Low affinity anti-AChR 
Abs, binding to clustered AChRs, have been found in 66% of seronegative 
generalized MG patients sera [106], but this test is not currently commercially 
available.  
 
Scan Exams 
Chest X ray computed tomography or Magnetic Resonance Imaging (MRI) are 
routinely performed in all patients with confirmed MG to exclude the presence of 
thymoma. However, contrast agents should be used with caution because they 
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might exacerbate myasthenic weakness [107]. MG often coexists with thyroid 
disease, so baseline testing of thyroid function should be obtained at the time of 
diagnosis [16]. 
1.2.5 Therapeutic Treatment  
 
The common therapeutic approach for the treatment of MG includes the use of 
cholinesterase inhibitors, short-term immune and long-term immune therapies. MG 
patients refractory to common therapies can try treatments with new 
immunosuppressive drugs such as cyclophosphamide and rituximab. In the case 
of thymoma or thymic hyperplasia, the patients undergo thymectomy surgery.  
 
Cholinesterase inhibitors 
Oral cholinesterase inhibitors increase the amount of AChR available for binding at 
the NMJ, and are the first-line treatment in patients with MG [108]. Pyridostigmine 
bromide is the most commonly used reversible cholinesterase inhibitor. The initial 
oral dose in adults is 15–30 mg every 4–6 h, which is increased and adjusted to 
maximise benefit and minimize side effects (diarrhoea, stomach cramps). 
Cholinesterase inhibitors rarely induce complete or sustained relief of MG 
symptoms and do not affect disease progression, but might be sufficient for 
adequate management in certain patients with non-progressive mild or purely 
ocular disease. Doses of pyridostigmine over 450 mg daily can induce worsening 
muscle weakness due to a depolarisation block of neuromuscular transmission. 
Cholinergic overdose is often accompanied by the muscarinic symptoms of 
hypersalivation, bradycardia, hyperhidrosis, lacrimation, and miosis [16].  
 
Short-term immune therapies 
Plasmapheresis and intravenous immunoglobulin infusion are used for short-term 
treatment of MG exacerbations and in cases of a rapid clinical response. 
Plasmapheresis temporarily reduces the concentrations of circulating anti-AChR 
antibodies [109]. Typically one exchange, removing one to two plasma volumes, is 
done every other day, up to a total of four to six times. Published reports indicate 
that plasma exchange effectively improves strength in most patients with severe 
MG [109]. Common side-effects include hypotension, paresthesias, infections and 
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thrombotic complications related to venous access [110]. Plasma exchange can 
also reduce coagulation factors, particularly in repeated treatments [111].  
Circulating anti-AChR pathogenic factors can also be removed using 
immunoadsorption columns, some of which use immobilized AChR as an 
immunoadsorbent [112]. Intravenous immunoglobulin infusion is widely used for 
patients with exacerbating MG. The exact mechanism by which intravenous 
immunoglobulins ameliorate the disease is not clear, but it likely involves 
competition with autoantibodies and Fc (Fragment, crystallisable region)-receptor 
binding on immunoglobulin [113]. The standard dosing regimen for intravenous 
immunoglobulin (1–2 g/kg) involves the infusion of large volumes and is very 
expensive. Although rare, severe complications do occur, some of which are 
related to the large volume and high viscosity of the infused preparation [114].  
 
Long-term immune therapies 
The long-term immune therapies are the most commonly used treatments in MG 
patients. Three main classes of drugs belonged to this category: corticosteroids, 
non-steroidal immunosuppressive agents and other immunosuppressive agents. 
  
Corticosteroids — Corticosteroids were the first immunosuppressant medications 
used in MG, and still remain the most commonly used immune-directed therapy 
[115]. Several studies demonstrated that steroid treatment, administered at 
various doses, had a good efficacy in more than 73% of the patients with 
generalized MG with an improvement or remission [116, 117]. Prednisone is a 
synthetic corticosteroid drug generally used in MG patients, who do not respond  
adequately to cholinesterase inhibitors [115]. Prednisone irreversibly binds to α 
and β glucocorticoid receptors (GR – present in all tissues) with high affinity. The 
steroid receptor complexes dimerize and interact with cellular DNA in the nucleus, 
binding to steroid-response elements and modifying gene transcription. The 
immunosuppressive actions of the drug involve the inhibition of gene transcription 
for COX-2, cytokines, cell adhesion molecules and inducible Nitric Oxide 
synthetase, determine blockage of Vitamin D3-mediated induction of osteocalcin 
gene in osteoblasts, modification of collegenase gene transcription and increased 
synthesis of annexin-1. Initially, prednisone can be administered at high doses 
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(0.75–1.0 mg/kg daily) and then gradually reduced or continued at low doses for 
many years. Approximately a third of patients have a temporary exacerbation after 
starting prednisone; this usually begins within the first 7–10 days with high 
prednisone doses and lasts for several days [117]. In patients with oropharyngeal 
or respiratory involvement, plasma exchange or intravenous immunoglobulin can 
be given before beginning prednisone treatment to prevent or reduce the severity 
of corticosteroid-induced exacerbations and to induce a more rapid response [16]. 
Some neurologists prefer to appoint prednisone with a low dose (10–25 mg) and 
gradually increase to 60–100 mg on alternate days [118]. Whereas corticosteroids 
are highly effective in MG, they usually must be given chronically, with significant 
risk for adverse events [119]. Prednisone should therefore be considered in all 
patients with ocular MG who do not achieve full control of symptoms with 
anticholinesterase medications. Although not definitive, evidence suggests that 
corticosteroid treatment might delay or reduce the frequency of progression of 
ocular MG to generalised disease [30]. 
 
Non-steroid immunosuppressive agents — Azathioprine is a pro-drug that, 
following oral administration, it is metabolized by the purine methyl transferase into 
the active 6-mercaptopurine, itself a purine synthesis inhibitor. 6-Mercaptopurine 
blocks DNA synthesis and thus inhibits T and B cell proliferation [16]. More studies 
indicate that azathioprine is effective in 70–90% of patients with MG, but the onset 
of benefit might be delayed for as long as 12 months [120, 121]. Azathioprine (50 
mg daily) can be used alone or as a steroid-sparing agent in MG. When these 
drugs are used in combination resulted more effective and better tolerated than 
administered alone [122]. In the absence of systemic side effects, the dose is then 
gradually increased by 50 mg per week to a daily dose of 2–3 mg/kg. 
Hepatotoxicity and leukopenia are important adverse effects [123], which can be 
reverted, if detected early, administrating reduced or discontinued doses of drug. 
Patients with thiopurine methyl transferase deficiency cannot completely 
metabolise azathioprine and a normal dose might lead to dangerous leukopenia 
[124]. Therefore, measurement of thiopurine methyl transferase concentrations is 
recommended before initiating azathioprine therapy. 
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Mycophenolate mofetil (MMF) is a pro-drug of mycophenolic acid and a reversible 
inhibitor of inosine monophosphate dehydrogenase (IMPDH) [125] in purine 
biosynthesis, thereby suppressing T and B cell proliferation [16]. MMF is selective 
for de novo pathways critical to lymphocytic proliferation and activation. Other cells 
are able to recover purines via a separate, scavenger pathway and are thus able 
to escape the effect. MMF represents an useful alternative to the highly toxic 
azathioprine. The standard dose used in MG is 1 g twice daily, but doses up to 3 g 
can be used. Higher doses are associated with myelosuppression, therefore MG 
patients should be constantly monitored with blood test. 
Ciclosporin inhibits T-cell proliferation via disruption of calcineurin signalling, 
binding the cytosolic protein cyclophilin of T-lymphocytes. This complex of 
ciclosporin and cyclophilin inhibits calcineurin, which is responsible for activating 
the transcription of IL-2, cytokine that interacts with its specific receptor and 
stimulate the growth, differentiation and survival of T cells via the activation of the 
expression of specific genes. In T-cells, activation of the T-cell receptor normally 
increases intracellular calcium, which acts via calmodulin to activate calcineurin. 
Calcineurin then dephosphorylates the transcriptional nuclear factor of activated T-
cells (NF-AT), which translocates from cytosol to the nucleus of the T-cell and 
sustains the expression of genes such as IL-2 and other pro-inflammatory 
cytokines. Ciclosporin prevents the dephosphorlyation of NF-AT by binding to 
cyclophilin inhibiting lymphocytes production and IL-2 release. Ciclosporin is used 
mainly in patients in which azathioprine is either ineffective or not tolerated. The 
recommended initial daily dose is 4–6 mg/kg nevertheless, daily doses of 3–4 
mg/kg or less are often adequate. Common side effects are hirsutism, tremor, gum 
hyperplasia, and anaemia, but hypertension and nephrotoxicity are the main 
treatment-limiting adverse reactions [126].  
Tacrolimus (FK506) has a mechanism of action similar to ciclosporin, with 
potential benefits for MG [127, 128]. Sustained benefit has been reported in anti-
ryanodine-receptor- positive patients, probably due to enhancement of ryanodine-
receptor-related sarcoplasmic calcium release [129]. Daily doses are of 3–5 mg, 
with a less nephrotoxicity compared to ciclosporin as side effect [16]. 
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Other immunosuppressive agents — A small percentage of patients with MG are 
refractory or develop intolerable side effects to treatment with corticosteroids in 
combination with one or more of the immunosuppressive agents. These patients 
can therefore be considered in treatments with cyclophosphamide and rituximab.  
Cyclophosphamide is a nitrogen mustard alkylating agent, which forms DNA 
crosslinks between (interstrand crosslinkages) and within (intrastrand 
crosslinkages) DNA strands at guanine N-7 positions. This reactions are 
irreversible and lead to cell death. Recent studies demonstrated that different 
doses of intravenous cyclophosphamide given to patients with refractory MG 
improved muscle strength and reduced steroid requirement [130-132]. Side effects 
of cyclophosphamide include myelosuppression, haemorrhagic cystitis, and an 
increased risk for infection and malignancy [133]. 
Rituximab is a chimeric monoclonal antibody directed against the B-cell surface 
marker CD20 (an activated-glycosylated phosphoprotein expressed on the surface 
of all B-cells, increasing with the maturation of cells). It reduces circulating B-cell 
counts, and on the basis of its potential for targeting autoreactive B-cell clones, 
might have a therapeutic role in antibody-mediated autoimmune diseases. 
Refractory and MuSK MG patients have reported benefits with this treatment 
[134]. 
 
Thymectomy 
The use of thymectomy in MG was initially based on empirical observations that 
patients with MG improved after removal of the thymus. The presumed role of the 
thymus in MG has provided theoretical justification for the procedure, and 
thymectomy has been used as a treatment for non-thymomatous MG for nearly 70 
years. The role of thymectomy in non-thymomatous MG patients is still not clear 
[16] even if some benefits arise from thymectomy and therefore it should be 
considered as a treatment option in selected patients with MG [135]. Most experts 
consider thymectomy as a therapeutic option in anti-AChR-positive, generalised 
MG with disease onset before the age of 50 years; some neurologists recommend 
it also in patients who lack anti-AChR antibodies [16]. Nowadays, the only 
absolute indication for thymectomy is the presence of thymoma. The role of 
thymectomy in anti-MuSK MG is not yet clear [27]. 
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1.3 EAMG 
 
Experimental Autoimmune Myasthenia Gravis is the animal model for human MG. 
It can be induced in vertebrates by active immunization with Torpedo Californica 
Electroplax AChR (TAChR) in Complete Freund‘s Adjuvant (CFA) as well as by 
passive transfer of MG sera or anti-AChR Abs [136, 137]. EAMG has been 
induced in a wide variety of experimental animals: rabbits [137], rats (Lewis strain 
is preferred, but Brown-Norway or Fisher might also be used) [138], guinea pigs 
[139], mice [140], and rhesus monkeys [141]. The most detailed models and 
studies have been performed in rats (65%) and mice (35%); the incidence of 
clinical EAMG in rats is higher (about 90%) than in mice (70-85%), thus indirectly 
indicating a superiority of the rat EAMG model [136]. Susceptibility to EAMG is 
influenced by age, sex and genetic background of different rat and mice strains 
[142].  
In particular experimental MG is induced in young (6-8 weeks aged) Lewis rats 
with a single administration of TAChR in CFA. Clinical signs of the disease are due 
to anti-TAChR antibodies cross-reacting with the self (rat) AChR on the NMJ. 
EAMG in Lewis rats is clinically characterized by two distinct phases: (1) a 
transient acute phase with a mild muscular weakness, beginning approximately 8-
10 days post immunization (p.i.) and recovering after 3-4 days; (2) a severe, 
progressive chronic phase starting approximately 25-30 days p.i., ending often in 
death [139]. 
The immunization with TAChR in CFA results in activation of specific-CD4+ T cells 
responding to the antigen of immunization, with consequent production of anti-
TAChR Abs cross-reacting with self-AChR and generation of anti-rat AChR Abs; 
this finding induces complement system activation and receptor and end-plate 
degradation, with consequent impairment of the nervous transmission from motor 
neuron to muscle at the NMJ. In particular, IgM directed to TAChR are readily 
detectable in rat serum during the acute phase of EAMG, while more than half of 
the antibody repertoire belong to IgG subtype, 10 days p.i; this suggests that a 
switch from IgM to IgG production has been very early occurred. During the 
chronic phase, 35 days p.i., all detectable anti-TAChR antibodies are IgGs. These 
late-IgGs cross-react with rat muscle AChR and, in this phase, the high affinity 
antibody populations may be represented by both Torpedo and Rat Abs [137]. As 
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EAMG progresses into its chronic phase, the titre of cross-reacting antibodies 
continues to increase [137], and the amount of AChR in muscle results greatly 
reduced. The initial AChR decrease during the early acute phase is due to an 
extensive phagocytosis of the post-synaptic membrane by macrophages. Indeed, 
during this phase muscle end-plates are invaded by phagocytic cells that intrude 
between nerve and muscle and phagocytize the post-synaptic membrane, thus 
resulting in functional denervation of up to 90% of the fibers. Around 10-12 days 
p.i., phagocytic cells disappear from the end-plate zone and the inflammatory 
response at the motor end-plate subsides. Thus, there is an increased yield of 
AChR that is presumably due to synthesis of extra-junctional AChR, occurring as 
consequence of denervation and to repair synthesis of junctional AChR. These 
processes probably occur for the rapid return of AChR yields to normal levels 
around 13 day p.i.. After the acute phase a continued gradual loss of AChR is 
observed. The development of the chronic phase is associated with dramatic 
increase in titre of serum antibody to muscle AChR, decrease in the area of post-
synaptic membrane and simplification of its folded structure. The impairment of 
neuromuscular transmission could result from decreased muscle AChR content, 
as the amount of receptor extracted from myasthenic muscles is greatly reduced, 
of about 30% compared to normal muscles. Furthermore, in chronic EAMG a large 
portion of the remaining AChR is complexed with antibodies, so that the function of 
these receptors in vivo may be partially or completely impaired [143]. 
The severity of EAMG in Lewis rats is monitored by evaluation of muscular 
weakness. Clinical score is based on the presence of tremor, hunched posture, 
reduced muscle strength and fatigability. The latter manifestation can be assessed 
after exercise (grip strength test: repetitive paw grips on the cage grid) for 30 
seconds. Disease severity is expressed as follows [139]: 
 grade 0: normal strength and no abnormalities; 
 grade 1: mildly decreased activity and weak grip or cry, more evident at the end 
of testing; 
 grade 2: clinical signs present before exercise (tremor, head down, hunched 
posture, weak grip); 
 grade 3: severe clinical signs present before exercise, no grip, moribund; 
 grade 4: dead. 
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EAMG rat models mimic many aspects of the pathophysiology of human MG, 
sharing various features with it. Thus, these animals provide an opportunity to 
explore therapeutic strategies of possible use in humans [136]. 
1.4 Role of the peptide R97-116 in EAMG 
 
The native AChR contains multiple antigenic determinants, both conformational (B 
cell epitopes) and linear (T cell epitopes), that are highly effective in activating the 
host immune system. Similarly to the human disease, Abs production in EAMG is 
thought to be under the control of AChR-specific T cells. The identification of 
immunodominant AChR sequences, relevant for T or B cell compartments that are 
effective in inducing EAMG, may be helpful to understand the key immunological 
processes leading to the disease and hence improve the knowledge of MG 
pathogenesis [138]. In some experimental models, myasthenogenic sequences 
were identified among B cell epitopes, located within the MIR of AChR α-subunit 
(α67–76) [144], or near the αBTX-binding site or acetylcholine-binding site, α125–
147 [145] and α183–200 [146] respectively. Anti-peptide Abs, able to bind to 
conformational extracellular domains of the AChR, can directly attack the receptor 
or interfere with the ACh-binding site. Indeed, rats immunized with α125–147 
sequence derived from Torpedo produce anti-peptide Abs that bind to the native 
receptor [147]. 
Baggi and colleagues have shown that EAMG can be induced in Lewis rats by a 
single injection of the peptide corresponding to the 97-116 sequence (R97-116) 
present on the rat AChR α-subunit and demonstrated that it plays an important 
role in the pathogenesis of the disease for its immunodominant properties [138]. 
As one single immunization with R97-116 has not been sufficient in inducing 
EAMG clinical manifestations, the immunization protocol have comprised one 
administration with peptide in CFA on day 0, followed by a booster injection of 
peptide in Incomplete Freund‘s Adjuvant (IFA) one month later. By this protocol, 
EAMG manifestations have become evident starting 7 weeks after the first 
immunization. When disease onset and progression have been compared to those 
observed in TAChR-induced EAMG, a slower progression has been observed in 
peptide-immunized rats. High incidence of the disease has been demonstrated in 
rats immunized with the self-peptide: more than 70% of animals have developed 
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EAMG, as confirmed by loss of body weight and clinical score,. elevated anti-rat 
AChR Abs and reduced muscle AChR content. In this model, Abs and T cells both 
specific for the peptide have been induced. R97-116-specific Abs have not exerted 
any myasthenogenic activity, because this sequence is hidden in AChR structure, 
but R97-116-specific T cells might recognize the self-peptide presented by muscle 
cells. Activated T cells might then exert cytotoxic activity toward the APCs, 
resulting in the release of native AChR, hence in breakdown of tolerance to AChR 
and in EAMG development [138]. 
1.5 Pixantrone 
 
The majority of MG patients show a positive response to standard treatments, 
nevertheless some require long-term immunosuppression with corticosteroids 
and/or immunosuppressive drugs. The importance of drug-related side effects 
(e.g. as a consequence of long-term treatment with corticosteroids) has been 
underlined in MG, as side effects might even lead to a degree of disability greater 
than that caused by MG itself. In this context, new immunosuppressants are 
needed for patients with intolerable side effects or with major contraindications to 
prolonged high-dose corticosteroid treatment.  
Pixantrone (PIX), also named BBR2778, is a novel aza-anthracenedione molecule 
with antitumor properties, developed to reduce the cardiotoxic effect of its 
analogue Mitoxantrone (MTX). The anti-tumor activity of PIX was evaluated in 
various hematologic and solid tumor animal models. Compared to MTX, PIX 
showed better anti-tumor activity in advanced leukemias and in human prostate 
carcinoma, and comparable anti-tumor activity in most solid tumor models [148]. 
Furthermore, while MTX is mostly effective at its maximum tolerated doses (MTD), 
PIX showed a high level of efficacy at approximately one third of its MTD [148].  
Now PIX is in trial in patients with solid tumors, leukemias and relapsed 
aggressive non-Hodgking‘s lymphoma, in which, given as a single agent, PIX 
demonstrated good activity [149, 150]. PIX, as MTX, is classified as 
immunosuppressant drug by the World Health Organization (WHO - Table 1.1), in 
the category of intracellular ligands for its antiproliferative action [151, 152]. 
Finally, preclinical studies in the experimental model of Multiple Sclerosis (MS) 
confirmed the immunosuppressive effects of PIX [153].  
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Category Drugs 
Intracellular ligands 
Antimetabolites 
Calcineurin Inhibitors 
Antiproliferative 
 
Azathioprine  
Cyclosporine A 
Mitoxantrone  
Pixantrone  
Cell surface ligands  Rituximab 
Natalizumab 
Anticytokine  Anti TNF  
Daclizumab  
 
Table 1.1 Immunosuppressant Classification by WHO [152]. 
1.5.1 Structure and mechanism of action 
 
Anthracyclines have been shown to be clinically very effective in some of tumor 
types, such as lymphoma, leukemia and breast cancer. For these diseases, 
anthracycline-containing chemotherapeutic regimens are effective as first-line 
initial treatment. However, they may cause cumulative heart damage that limits 
lifetime dosage and does not allow further re-treatment. PIX has been designed to 
reduce the heart damage compared to currently available anthracyclines or 
anthracenediones without a loss in anti-tumor activities.  
PIX contains an aza-anthracenedione molecular structure and, such MTX, shares 
some general similarities with anthracyclines, as the central quinoid ring (Ring-b in 
Figure 1.7).  
 
Figure 1.7 Chemical Structure of PIX and MTX, adapted from Baggi et al., 2009 [154].  
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The main differences between the two compounds reside in Ring-a, where the 
typical 5,8-dihydroxy-substitution pattern of MTX is substituted with pyridin ring, 
and in Ring-c, where both side-chains have a primary amino group more 
susceptible to formaldehyde activation and consequently has a greater potential to 
form complexes with DNA [155]. As a result of these structural differences, PIX is 
not subject to oxidative metabolism with formation of free radicals, allowing less 
severe toxic effects and decreased cardiotoxicity compared to MTX [156]. 
In vitro and in vivo studies demonstrated the effects of PIX in murine and human 
tumor cell lines and in tumor animal models, showing that PIX maintain a high 
level of activity in a wide range of doses despite of its significantly reduced 
cytotoxicity in comparison to MTX [156]. However, the mechanism of PIX 
cytotoxicity has not yet been well elucidated: although PIX intercalates DNA (due 
to its anthracenedionic structure) and inhibits topoisomerase II, DNA damage 
seems to be not correlated with cytotoxicity [157]. DNA topoisomerase II is 
associated with the nuclear matrix of interphase cells and is a major constituent of 
the chromosome scaffold. The latter plays essential roles in chromosome 
condensation and separation of daughter DNA molecules at the end of DNA 
replication (decatenation). Topoisomerase II is a DNA-relaxing enzyme, which 
removes DNA supercoiling and torsional tension as they arise during transcription 
and DNA replication [158]. DNA topoisomerase II has been identified as the target 
of a number of DNA intercalators, including anthracyclines (doxorubicina), 
anthracenediones (MTX) and aza-anthracenediones (PIX) [158]. DNA-damage 
induced by PIX may result from an alternative mechanism, i.e. ―poisoning‖ of the 
topoisomerase-DNA complex, that in turn prevents the formation of a cleavable 
complex. 
1.5.2 Pharmacokinetic  
 
Pharmacokinetic data for PIX in rodents indicate a multi-exponential clearance 
with a rapid decline in drug concentration during the distribution phase, followed by 
a slow and prolonged elimination phase lasting up to 192 h (equal to 8 days – 
Figure 1.8) [159].  
Since it is poorly absorbed orally, PIX is usually administrated intravenously (i.v.), 
allowing a rapid distribution throughout the body with accumulation in some tissue 
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compartments. In studies with radiolabelled PIX, the highest percentages of the 
administered dose were found in the skeletal muscles, liver and kidneys of mice 
and rats [159]. Less than 0.05% of the administered dose was found in the brain, 
suggesting that the drug and its metabolites do not cross the blood brain barrier. 
The efficiency of unchanged drug elimination from the systemic circulation was 
also shown to be high, but the metabolites (derived primarily from acetylation 
metabolism) were cleared more slowly with a greater volume of distribution. The 
terminal half-lives of PIX and total radioactivity derived from the plasma data were 
2.9 h and 78.6 h in mice and 7.1 h and 81.9 h in rats, which suggested that PIX 
has a large volume of distribution with a relatively slow clearance of the drug and 
its metabolites [159].  
PIX pharmacokinetics in human determined by HPLC assessment of PIX 
concentration in plasma and urine (treatment dosage of 180 mg/m2), showed that 
the drug has a large volume of distribution (21.4 l/kg) and a rapid clearance (1.15 
l/h/kg): its terminal half-life was 14.1 h, and PIX urinary elimination as unchanged 
drug was less than 10% [159]. 
 
 
Figure 1.8 PIX pharmacokinetic in rodents, Cell 
Therapeutics, Investigator‘s Brochure, 2002  [159]. 
1.5.3 Toxicity 
 
The acute toxicity tests of PIX in rodents after a single i.v. injection are used to 
define the lethal dose in 10% of animals - LD10 (65.4-77.8 mg/Kg for mouse males 
and females, respectively) and lethal dose in 50% of animals - LD50 (77.8-84.9 
mg/Kg for mouse males and females, respectively). In rats, the corresponding 
values are: LD10 98.1-65.2 mg/Kg and LD50 119.5-111.5 mg/Kg (table 1.2) [159]. 
The main symptoms in the acute toxicity tests after i.v. injection are: dyspnea, 
 40 
 
piloerection, reduced motility, swollen snout and blue pigmentation of the skin. 
These symptoms last no longer than four days with the exception of blue 
pigmentation that persists for the whole study period. Moreover the body-weight of 
the animals decrease in a dose-dependent manner (more evident in males) and a 
complete recovery is observed in females at the end of the study [159]. The 
histopathological examinations of the organs of rats treated with high dose of PIX 
show degenerative atrophy of spleen, bone marrow, gastrointestinal mucosa and 
kidney [160]. Animals receiving single or repeated toxic dosages of PIX do not 
present myocardial lesions typical of treatments with anthracyclines and 
anthracenediones (MTX) [159]; PIX results also less myelosuppressive than MTX 
[69, 161]. These studies confirm the low cardiotoxicity of PIX as one of its most 
important features. 
 
Rat’s Gender Lethal dose i.v. (mg/Kg) 
Male  LD10 
LD50 
98.1 (74.6 - 108.0) 
119.0 (109.0 - 131.7) 
Female  LD10 
LD50 
65.2 (58.1 - 72.2) 
111.5 (103.8 - 119.2) 
 
Table 1.2 Acute toxicity of PIX administrated i.v. in rat [159]. 
1.5.4 Immunosuppresant potential of Pixantrone  
 
Immunosuppressive drugs are effective in the treatment of various autoimmune 
diseases; however, their prolonged use is hampered in most cases by severe side 
effects [162]. Several lines of evidence link immunosuppression to inflammation in 
patients with MS and provide a rationale for the increasing use of 
immunosuppressive drugs in the treatment of MS [153]. Various 
immunosuppressive agents have been tested in pre-clinical studies, such as on 
Experimental Autoimmune Encephalomyelitis (EAE), the animal model of 
demyelinating MS disease, in which axonal loss is the consequence of 
inflammation and T-cell infiltration in the nervous system, resulting effective in 
preventing and treating the disease [151]. Topoisomerase II inhibitors (initially 
MTX) were also used as immunosuppressant agents in the experimental model of 
arthritis [163], and pre-clinical in vitro and in vivo studies in EAE models have 
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demonstrated that MTX is effective in reducing T- and B-cell numbers, in 
suppressing humoral immunity and T-helper cells [164]. Moreover, various clinical 
trials in MS patients confirmed its immunosuppressive effect [165]. Compared with 
other immunosuppressant drugs, MTX show two important benefits: the immediate 
tolerance and a more comfortable treatment regimen for the patients [151]. Unlike 
other immunosuppressants, MTX induces apoptosis of B lymphocytes in 
peripheral blood [166] and ex vivo analysis of the cytokine profile of immune cells 
from MS patients treated with MTX, has revealed a long-lasting decrease of IL-10 
expressed in monocytes and of IL-2R1 expressed in T cells [164]. This drug has, 
therefore, been approved for MS treatment in the USA and Europe [165]. 
Nevertheless, severe long-term side effects may be associated with its prolonged 
use: cardiotoxicity is the major side effect, and it is strictly dependent on the total 
cumulative dose. Moreover, cases of therapy-related acute leukaemia have been 
reported after MTX therapy for MS [167]. 
Due to its close chemical relationship with MTX, PIX has been also studied and 
evaluated as immunosuppressive/antiproliferative drug, thanks to its ability to 
interfere with DNA structure during cell cycle and cell duplication, events that play 
a crucial role during immune activation processes in autoimmune diseases [163]. 
Several studies evaluated the effect of PIX in vivo in acute and chronic EAE 
models, and in vitro on antigen- and mitogen-induced T-cell proliferation. In 2004, 
Cavaletti and colleagues demonstrated that PIX modified the course of acute and 
relapsing-remitting EAE in rats [148]. The reduced EAE severity in PIX-treated rats 
was due to the marked and long-lasting effect of the drug on lymphocyte 
subpopulations and to the suppression of antigen-specific responses dose-
dependently: circulating CD4+ and CD8+ cells were markedly reduced until the end 
of the experiment; a very evident effect was also observed on CD45RA+ B cells. 
The antigen-specific autoantibody response to myelin basic protein was also 
abolished by the highest dose of PIX and MTX. Moreover, PIX was similarly active 
on in vitro human peripheral blood cells and rat cells [148]. Experimental data 
indicate that PIX is as potent as MTX to prevent EAE development as well as 
relapses in established disease [151]; nevertheless, PIX has a higher safety profile 
compared to MTX, and can represent a potential immunosuppressant agent in 
clinical trial in MS [148]. 
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1.5.5 Pixantrone in EAMG 
 
MG is probably the most thoroughly understood autoimmune disease of the 
nervous system [168]. Current therapies aim to restore the functional pool of 
AChR at the NMJ, by depleting anti-AChR specific Abs and by suppressing the 
autoimmune response at T cell level [169]. However, prolonged drug treatments 
(i.e. corticosteroids) can be required with high risk of severe side effects [168] and 
some subjects do not respond to conventional therapies. In this context the 
investigation of new immunosuppressive drugs is needed and the availability of 
experimental models for MG allows to study innovative therapies aiming the 
suppression/modulation of disease manifestations [170]. 
Evaluating Pixantrone efficacy in MG is important, since PIX (as MTX) mediates a 
complex immune suppression involving both B and T lymphocytes [171]. In 2008, 
Ubiali and colleagues have investigated the effects of PIX in EAMG Lewis rats [1]. 
Firstly, PIX has been tested in vitro on R97–116-specific T cell lines, grown from 
R97-116-immunized rats, [138]. T cells have been challenged with their specific 
peptide (R97-116 5 µg/ml) or with Concanavalin A (ConA 2 µg/ml – aspecific 
mytogen as positive control) in the presence of PIX (range 0.01–10 μM). Results 
have showed that, already at the lowest concentration ([PIX] = 0.01 µM), a 
significant reduction of Ag-specific as well as ConA-induced T cell responses has 
been observed. Micromolar concentrations of PIX almost completely abrogated T 
cell responses. PIX efficacy on ex vivo lymphocytes proliferation has been tested 
by intravenously (i.v.) administration, at a dosage of 16.25 mg/kg, into TAChR-
immunized Lewis rats, 28 days p.i.; the treatment has been performed once 
weekly for three times (q7dx3). This dosage has been equal to 1/4 of the LD10 in 
female rats (65.2 mg/Kg of PIX administrated i.v. [159]). Both spleens and lymph 
nodes (LN) have been aseptically removed one week after the last treatment, total 
cell count and cell viability have been evaluated. Total splenic cell count have 
been found decreased in the PIX-treated animals compared to the vehicle-treated 
ones and PIX effect has been even more dramatic in draining LNs. The expression 
of CD3, CD4, and CD8 molecules, as T-cell markers, has been studied by FACS 
analysis on both spleen and LN cells (LNCs) populations; results have not shown 
any effects of the drug on the percentage of T-cell subsets, among living cells. Ex 
vivo proliferative responses from LNCs, challenged with TAChR (1.25 and 0.25 
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μg/ml), Torpedo and Rat AChR 97–116 peptides (10 μg/ml), have been found 
reduced compared to the vehicle-treated animals [1]. Secondly, PIX efficacy has 
been assessed in EAMG Lewis rat model, by a preventive treatment protocol (i.e. 
starting before the onset of clinical manifestations) and by a therapeutic protocol 
(i.e. starting after the onset of symptoms), in order to observe effects in delaying or 
modulating ongoing EAMG, respectively. The preventive treatment have started 4 
days after TAChR immunization, while the therapeutic treatment have started 4 
weeks after immunization; PIX has been administrated i.v. at the dosage of 16.25 
mg/kg, once a week for three times (q7dx3 – representative of 1/4 of PIX LD10 in 
female rats, cumulative dosage 48.75 mg/Kg) for both treatment schedules. 
Animals have been scored every other day by assessing their body weight and 
muscular strength [139]. Results have indicated that both therapies have modified 
the course of the disease, according to increased body weight and decreased 
EAMG score, in PIX-treated rats compared to the vehicle. Biochemical and 
immunological assays have confirmed PIX efficacy: treated animals have 
significantly shown an increased muscle AChR content and a reduced anti-Rat 
AChR Abs titer. Ex vivo proliferative LNCs responses to TAChR have been 
affected by both PIX protocols, whereas to ConA-induced have been unaltered. 
The pathological examination of hearts collected from PIX- and vehicle-treated 
rats have not shown signs of cardiotoxic damage, confirming the drug safe profile 
[1]. Therefore, PIX has able to modulate EAMG clinical symptoms, proving 
effective ameliorating actions, both in preventive and therapeutic treatments, and 
showing ex vivo effects on immune cell count, similar to those reported on 
circulating lymphocytes in PIX- treated EAE [148].  
These data indicate that PIX might be a promising immunomodulatory agent for 
clinical investigation in MG [154], but more studies are necessary in order to better 
investigate the use of alternative schedules and PIX related toxicity. 
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Chapter 2 – Aim of the study 
 
As mentioned above, some MG patients are non-responsive to the commonly 
used immunotherapies, or develop severe side effects. In this regard, new potent 
but well-tolerated immunosuppressive drugs are needed for treatment-resistant 
MG, for patients with intolerable side effects or with major contraindications to 
high-dose corticosteroid treatment. Pixantrone can play an important role due to its 
anti-proliferative and immunosuppressive properties. Indeed, PIX has been tested 
in MS animal model [148, 171], resulting effective in the modulation of EAE; hence 
a clinical study (phase 1) has been proposed in MS patients [152]. Recently, Ubiali 
and colleagues have demonstrated the effect of PIX in the preventive and 
therapeutic treatments of EAMG; the drug has been able to ameliorate clinical 
symptoms and myasthenic typical ex vivo parameters when administrated i.v. at 
the dose 16.25 mg/kg (1/4 of PIX LD10 q7dx3), with a cumulative dosage of 48.75 
mg/Kg [1].  
In the current research project we have focused our attention to the therapeutic 
treatment of EAMG; in particular, the aim of our study has been to evaluate 
different PIX treatment schedules, in order to identify the lowest dosage able to 
ameliorate ongoing EAMG, thus further lowering the risk of toxic effects. 
For this purpose, we have analyzed two aspects: 
1. In vitro studies: 
 We have evaluated the lowest concentration of PIX able to reduce lymphoid 
cells proliferation, to determine its pharmacological effects on distinct cell 
subpopulations, each with different proliferative responses. For this 
purpose, we have tested the drug, in a logarithmic range of concentrations 
(from 0.1 pM to 1 µM), on various cell populations: a) CD4+ T cell lines 
specific for R97-116 peptide (≥ 90% of cells in active proliferation); b) 
lymphocytes and splenocytes isolated from R97-116-immunized rats, 
sacrificed 10 days p.i. (20-40% of cells in active proliferation); c) 
splenocytes from healthy rats and peripheral blood mononuclear cells 
(PBMCs) from healthy human donors (5-10% of cells in active proliferation). 
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 We have studied PIX toxic effects on differentiation of myeloid precursor 
cells, derived from bone marrow of healthy rats. Myeloid precursors have 
been differentiated in immature dendritic cells (iDCs) and exposed at day 0 
and day 3 to various PIX concentrations (0.1nM, 1nM, 10nM, 10µM), during 
their differentiation process. At the end of the exposure, we have analyzed 
iDCs viability. 
These studies allowed us to evaluate the lowest concentration of PIX able to 
generate anti-proliferative responses and correlate its pharmacological effects 
to toxic effects in vitro. Both these aspects have been essential for the 
assessment of new therapeutic schedules in EAMG rats. 
2. In vivo studies: 
 Firstly, we have tested the effect of a single administration of PIX in TAChR-
primed rats: animals were immunized with TAChR and i.v. treated 24 hours 
later with different concentrations of the drug: 16.25 mg/Kg (1/4 of PIX 
LD10), 8.12 mg/Kg (1/8 of PIX LD10), 4.06 mg/Kg (1/16 of PIX LD10);  
 Secondly, we have modified the schedule of administration, but not the PIX 
cumulative dosage previously studied (48.75 mg/Kg) [1]. TAChR-immunized 
female Lewis rats have been treated, starting 4 weeks p.i., with different 
schedules: PIX 8.12 mg/Kg, q7dx6; PIX 16.25 mg/Kg, q14dx3; vehicle, 
q7dx6.  
 Finally, we have decreased the PIX cumulative dosage to 24.36 mg/Kg 
(50% of the studied dosage), with two different PIX treatments: PIX 4.06 
mg/Kg, q7dx6; 8.12 mg/Kg, q14dx3; vehicle, q7dx6. TAChR-immunized 
female Lewis rats have been treated with PIX starting at week 4 p.i.  
During all the experiments, EAMG rats have been monitored for body weight and 
clinical score. At the end of the experiment (11 weeks p.i.), we have performed ex 
vivo analysis (e.g. proliferation assay, anti-rat AChR Abs titer) to evaluate the 
efficacy of PIX treatments. 
The ultimate goal of our study is to further evaluate the potential of Pixantrone-
based therapeutic approach in the experimental model of Myasthenia Gravis by 
optimizing/refining the published schedule of treatment [1]. Our data will be the 
basis for the design of a clinical study in MG patients non-responsive to common 
therapies. 
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Chapter 3 – Materials and Methods 
 
3.1 Pixantrone  
 
BBR2778 (Pixantrone, 6,9-bis {([(2-amino) ethyl] amino) benzo[g]isoquinoline-
5,10-dione dimaleate}) is a novel aza-anthracenedionic derivate with 
immunosuppressive properties, developed by Cell Therapeutics, Inc. (Seattle, 
USA). Pixantrone is a blue lyophilized powder (PM=557.52), reconstituted with 
sterile saline solution (0.9% NaCl, B. Braun, Milan, Italy) and added in vitro in cell 
cultures or administered intravenous (i.v.) in healthy and EAMG rats [159]. 
3.2 Animals 
 
Female Lewis rats, 6–8 weeks of age, have been purchased from Charles River 
Laboratories (Calco, Italy) and housed at the animal facility of the Neurological 
Institute Foundation Carlo Besta (Milan, Italy). Experiments have been approved 
by the Ethic Committee of the Institute and performed in accordance with the 
Principles of Laboratory Animal Care (European Communities Council Directive 
86/609/EEC). Animals have been sacrificed after deep anesthesia obtained by 
carbon dioxide; low-grade anesthesia with 4% chloral hydrate (Sigma-Aldrich, St. 
Louis, MO) administered intra peritoneal (i.p.) has been used for immunizations 
and treatments. 
3.3 Antigens 
 
AChR has been purified from Torpedo Californica Electroplax tissue (Aquatic 
Research Consultants, San Pedro, CA) by affinity chromatography on Naja-naja 
siamensis toxin coupled to Sepharose 4B (GE Healthcare Life Sciences, 
Piscataway, NJ) [172]. The purified receptor has been analyzed on SDS PAGE. 
TAChR preparations have been dialyzed extensively against 0.01 M Tris-HCl (pH 
7.5), 0.001 M EDTA, 0.1 M NaCl (Tris-HCl buffer), and 0.1% Triton X-100 (all from 
Sigma-Aldrich, Milan, Italy). TAChR, used for T cell proliferations, has been further 
dialyzed against Tris-HCl buffer plus 0.025% Triton X-100 and filter-sterilized (0.2 
mm). 
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The peptide R97–116, corresponding to region 97–116 of the rat AChR α-subunit, 
has been synthesized by Dr. Longhi (C.N.R., Milan, Italy), according to sequences 
already published in GenBank (http://www.ncbi.nlm.nih.gov/genbank/; accession 
number X74832 for rat AChR, sequence DGDFAIVKFTKVLLDYTGHI). R97-116 
has been synthesized using F-moc chemistry on a 431A automated peptide 
synthesizer (PE Applied Biosystems, Foster City, CA). The peptide has been 
purified by reverse-phase HPLC and the synthesis has been confirmed by mass 
spectroscopy. 
3.4 In vitro studies 
3.4.1 Evaluation of PIX IC50 in different cell subpopulations 
 
R97-116 specific T cell lines 
Female Lewis rats (n=3) have been immunized with 50 µg of R97–116 of the rat 
AChR α-subunit in CFA (Difco Laboratories Inc, Detroit, MI), added with 
Mycobacterium tuberculosis H37Ra (inactivated strain, Difco Laboratories). Lymph 
nodes have been aseptically removed 10 days post immunization and processed 
into a single-cell suspension. LNCs have been cultured, at 37°C with 5% CO2, in 
Roswell Park Memorial Institute Medium (RPMI) 1640 medium, supplemented 
with, 1% Na-pyruvate, 1% non-essential amino acids, 1% L-glutamine, 1% 
penicillin-streptomycin (all from Euroclone Spa, Milan, Italy), and 5x10-5 M 2-
mercaptoethanol (2-ME, BDH, Milan, Italy), defined completed RPMI medium, plus 
10% Fetal Bovine Serum (FBS, Gibco, Monza, Italy) and stimulated with 5 µg/ml of 
R97–116 peptide. Every 15 days, cells (3x105 cells/well) have been re-stimulated 
in co-culture with irradiated (3000 cGy) splenic cells (SPNs, 2x106 cells/well) from 
healthy donor (HD) rats, used as APCs source, in presence of the specific peptide. 
Every 3–4 days, R97-116-specific T cells have been expanded with IL-2 [173]. The 
cell number has been counted by trypan blue exclusion dye technique. 
The proliferative capability of R97-116-specific T cells (3x104 cells/well) has been 
evaluated (in triplicates) in co-culture with irradiated SPNs (2x105 cells/well) and in 
presence of the peptide (5 µg/ml), in completed RPMI medium added with 2% 
normal rat serum. 2 µg/ml ConA (Sigma-Aldrich) has been used as positive 
control. 
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Cells have been exposed to different concentrations of PIX or to Phosphate Buffer 
Saline (PBS, Euroclone Spa, Milan, Italy), as vehicle. After 72 h of culture, T cells 
have been tested in proliferation assays. 
LN and SPN cells from healthy and primed rats  
LNCs and SPNs have been aseptically removed from healthy (n=3) and R97-116-
immunized (n=3) female Lewis rats (10 days p.i.) and processed into a single-cell 
suspension. Cell number has been counted by trypan blue exclusion dye 
technique. LNCs and SPNs (2x105 cells/well) have been cultured, at 37°C with 5% 
CO2, in presence of R97–116 peptide (5 µg/ml) or ConA (2 µg/ml) in completed 
RPMI medium plus 2% normal rat serum and exposed to different concentrations 
of PIX or PBS, as vehicle. After 72 h of culture, cells have been tested in 
proliferation assays [173]. 
Peripheral blood mononuclear cells from human healthy donors  
Peripheral blood mononuclear cells (PBMCs) have been isolated from blood of 
unrelated human HD by centrifugation over a Ficoll-PaqueTM Plus (Amersham 
Biosciences, Milan, Italy) gradient and re-suspended in RPMI 1640 medium, 
supplemented with 5% human male serum type AB (Sigma–Aldrich, Milan, Italy), 
1% Na-pyruvate, 1% non-essential amino acids, 1% L-glutamine, 1% penicillin–
streptomycin and 5x10-5 M 2-ME [174]. Cell number has been counted by trypan 
blue exclusion dye technique. PBMCs (2x105 cells/well) have been challenged 
with 10 µg/ml phytohaemagglutinin (PHA, aspecific mitogen, Sigma-Aldrich) and 
exposed to different concentrations of PIX or PBS, as vehicle. After 72 h of culture, 
at 37°C with 5% CO2, cells have been tested in proliferation assays. 
Proliferation Assay  
The proliferation assay allows determining the number of cells that are growing in 
presence or absence of certain proliferation-affecting agents. In this study, 
logaritmic concentrations of PIX (0.1 pM – 1 µM) or vehicle (PBS) have been 
added to stimulated cells (see above), in 96-well culture plates (Corning Life 
Science, Chorges, France). After 72 h, at 37°C with 5% CO2, cells have been 
incubated with [3H]-thymidine (0.5 µCi/well, Perkin Elmer, Burnsville, MN). After 
further 16-18 h of culture, plates have been harvested and counted on a Wallac 
MicroBeta TriLux Counter (PerkinElmer) [173]. Results from in vitro PBS treated 
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cells, obtained as counts per minute (cpm), have been expressed as mean cpm ± 
SE proliferation response for each conditions, from three independent 
experiments. 
Determination of PIX IC50  
The half maximal inhibitory concentration (IC50) is a measure of the efficacy of a 
compound in inhibiting cellular biological functions. In this study, quantitative 
measure indicates the amount of PIX necessary to halve the proliferation of 
different cell populations, as pharmacological effect.  
The IC50 of the drug has been determined evaluating the proliferation values % 
normalized to vehicle of each PIX-treated subpopulation and constructing a dose-
response curves (GraphPad Prism, CA), to examin the effect of different 
concentrations of the drug on cells stimulated with aspecific or specific antigens 
(see above). Results have been expressed as mean of IC50 ± SE of three 
independent experiments. 
3.4.2 PIX toxicity on differentiation of Myeloid Precursor Cells 
 
Tibiae and femurs have been aseptically removed from healthy female Lewis rats 
(6-8 weeks of age; n=3) and after the complete removal of the muscle; bones have 
been washed in 70% ethanol, for 2 minutes, and twice rinsed in sterile PBS. After 
removal of epiphysis, bone marrow has been pushed through a syringe, into a 
sterile petri-dish (Corning Life Science, Chorges, France) containing RPMI 1640 
medium and processed in a single-cell suspension. After osmotic lysis, in sterile 
H2O at 4°C for 30 seconds, in order to completely eliminate erytrocytes, Myeloid 
Precursor Cells (MPCs) have been re-suspended in the same medium and 
counted by trypan blue exclusion tecnique. At day 0 (t=0), MPCs (1x106 cells/ml) 
have been cultured, at 37°C with 5% CO2, in completed RPMI medium for 2 h. 
Then non-adherent cells have been removed and myeloid precursors have been 
cultured (t=0) in completed RPMI medium plus 10% FBS, in presence of 5 ng/ml 
rat Granulocyte-Macrophage Colony Stimulating Factor (rGM-CSF – Pepro Tech, 
London, UK) and 5 ng/ml rat Interleukine 4 (rIL-4 – Pepro Tech): these cytokines 
are involved in the differentiation of MPCs into immature Dendritic Cells (iDCs). 
After 3 days of culture (t=3), fresh medium containing rGM-CSF (5 ng/ml) and rIL-4 
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(5 ng/ml) has been added. The differentiation of MPCs in iDCs occurs in 7 days of 
culture (t=7) [175].  
At t=0 or t=3 of this differentiation process, cells have been exposed to PIX at the 
following concentrations: 0.1 nM, 1 nM, 10 nM, 10 µM. At the end of the 
experiment (t=7), cells have been counted by trypan blue exclusion technique and 
their viability has been evaluated as the ratio between living and total cell counts 
(living and dead cells). These data have been expressed as mean ± SE of three 
independent experiments.  
3.5 In vivo evaluation of PIX efficacy on EAMG rats 
3.5.1 Immunization and treatment protocols 
EAMG has been induced in female Lewis rats (6–8 weeks of age) by immunization 
into hind footpads with 50 μg purified TAChR in CFA (Difco Laboratories Inc.) 
supplemented with 1 mg/rat H37Ra.  
The effect of different PIX dosages has been firstly evaluated on TAChR-
immunized rats (n=4, for each treatment group), receiving i.v. (via tail vein) a 
single dose of the drug, 24 h post immunization (16.25 / 8.12 / 4.06 mg/Kg PIX), 
and sacrificed 10 days after. Single-cell suspensions, from draining lymph nodes 
of these animals, have been challenged in vitro with TAChR (0.25 and 1.25 µg/ml) 
or ConA (2 µg/ml), as positive control. In parallel, we have been evaluated the 
effect of the highest concentration of PIX (16.25 mg/Kg) in a single dose on 
healthy rats (n=3), defined HD/PIX, to assess the drug toxicity in physiological 
conditions. 
Secondly, we have evaluated the efficacy of PIX treatments in a therapeutic 
schedule. PIX has been administered i.v. at the onset of the typical EAMG clinical 
signs (4 weeks p.i.) by two different cumulative dosages: 48.75 mg/Kg (1/4 of the 
LD10 in rats [1]) and 24.36 mg/Kg (1/8 of the LD10). AChR-immunized rats have 
been randomly assigned to different experimental groups and administered as 
follow: 1) 16.25 mg/Kg, q14dx3 (16.25x3 group), for a cumulative dosage of 48.75 
mg/Kg (n=3), as positive control; 2) 8.12 mg/Kg, q7dx6 (8.12x6 group), for the 
same cumulative dosage (n=6); 3) 8.12 mg/Kg, q14dx3 (8.12x3 group), for the 
cumulative dosage halved compared to the former (n=6); 4) 4.06 mg/Kg, q7dx6 
(4.06x6 group) for the cumulative dosage of 24.36 mg/Kg (n=6); 5) sterile saline 
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solution (0.9% NaCl), q7dx6 (vehicle group), as negative control (n=7). In parallel, 
we have evaluated the effect of the highest concentration of PIX (16.25 mg/Kg) in 
three different injections (q14dx3, cumulative dosage of 48.75 mg/Kg) on healthy 
rats (n=3); this investigation has assessed a potential toxicity of repetitive drug 
administrations on physiological conditions. 
3.5.2 EAMG clinical evaluation  
 
Disease manifestations in EAMG rats have been evaluated by measuring body 
weight and testing muscular weakness. Clinical score has been based on the 
presence of tremor, hunched posture, low muscle strength and fatigability, and 
assessed after exercise (repetitive paw grips on the cage grid) for 30 seconds, 
using the grip strength test. 
Disease severity has been commonly graded as follows: grade 0, normal strength 
and no abnormalities; grade 1, mildly decreased activity and weak grip or cry, 
more evident at the end of testing; grade 2, clinical signs present before exercise 
(tremor, head down, hunched posture, weak grip); grade 3, severe clinical signs 
before exercise, no grip, moribund; and grade 4, dead [139]. 
Each animal has been weighed and scored twice weekly, until 4 weeks p.i., and 3 
times a week, until the end of the experiment. EAMG has been confirmed by 
edrophonium chloride (Sigma-Aldrich) test. Results have been expressed as mean 
± SE of body weight and clinical score for each animal at each time point. Data 
have been derived from three independent experiments. 
3.5.3 Effects of PIX on ex vivo proliferative responses to TAChR 
 
Popliteal and inguinal lymph nodes have been aseptically removed from PIX- or 
vehicle-treated female Lewis rats (11 weeks after TAChR-immunization), 
processed into single-cell suspensions and counted by trypan blue exclusion 
tecnique. LNCs (2x105 cells/well) have been seeded in triplicates, in 96-well 
culture plates (Corning Life Science, Chorges, France), in presence of TAChR 
(0.25 and 1.25 µg/ml) or ConA (2 µg/ml), as positive control; these stimuli have 
been previously diluted in completed RPMI medium plus 2% normal rat serum. 
After 72 h of culture, at 37°C with 5% CO2, 0.5 µCi of [
3H]-thymidine has been 
added to each well and cells have been harvested after further 16–18 h. Results 
from three independent experiments have been expressed as proliferation values 
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% normalized to vehicle of each PIX-treated group ± SE. The data from control 
wells (medium alone) were reported as mean cpm ± SE of proliferative responses. 
3.5.4 PIX myelotoxicity in vivo 
 
Tibiae and femurs have been aseptically removed from PIX- and vehicle-treated 
female Lewis rats, 11 weeks after TAChR-immunization.  
Following the procedure previously described (paragraph 3.4.2), single-cell 
suspensions have been obtained and cells counted by trypan blue exclusion [175]. 
The myelotoxicity of PIX treatments has been evaluated as the ratio between living 
and total cell counts (living and dead cells). Data from three independent 
experiments have been expressed as mean ± SE. 
3.5.5 Real Time qPCR 
 
Total RNA has been extracted from SPNs of EAMG and HD rats, treated with PIX 
or vehicle, using Trizol reagent (Invitrogen, Carlsbad, CA). cDNA has been 
synthesized from RNA using random hexamers (GE Healthcare Life Sciences 
Europe GmbH, Milan, Italy) and reverse transcriptase (Moloney murine leukemia 
virus; Life Technologies, Carlsbad, CA).  
Real-time quantitative PCR (TaqMan-qPCR, Applied Biosystems, Foster City, 
California) for IFNγ (http://www.ncbi.nlm.nih.gov/nuccore/, Reference Sequence 
NM_138880) has been performed using Assay-on Demand Gene Expression 
Products (Applied Biosystems, Foster City, CA). β Actin (Applied Biosystems, 
http://www.ncbi.nlm.nih.gov/nuccore/, Refarence Sequence NM_031144) has 
been used as endogenous control. Real-time PCR reactions of each gene have 
been performed in triplicates with an ABI Prism 7500 FAST Real-Time PCR 
System (Applied Biosystems). Levels of mRNA expression for each gene have 
been calculated using the 2-ΔCt method [176], in which ΔCt represents the 
difference between cycle threshold (Ct) of the target gene and Ct of the house-
keeping gene. Data, from three independent experiments, have been represented 
as 2-ΔCt x100 and expressed as mean (%) ± SE. 
3.5.6 Anti Rat-AChR Antibodies Assay 
 
Anti-rat AChR Abs have been assayed in individual sera by conventional radio-
immunoprecipitation method [177]. Rat AChR has been extracted from healthy rat 
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muscle and labeled with 2x10-9 M [125I]-αBTX (Perkin Elmer). Sera from HD 
(negative control), PIX- and vehicle-treated rats have been incubated over-night 
(ON) with radio-labeled rat AChR. Ab–AChR complexes have been precipitated by 
adding rabbit anti-rat IgG (Sigma-Aldrich, Milan, Italy). Immuno-precipitates have 
been washed twice with 1 ml cold PBS 0.5% Triton X-100 (Carlo Erba, Milan, Italy) 
and [125I]-αBTX labeling has been evaluated by γ-counter (Perkin Elmer). A 
parallel assay has been performed on radio-labeled rat AChR co-incubated with 
unlabeled α-BTX (Invitrogen, Milan, Italy) to eliminate aspecific binding rate. Anti-
AChR Ab titers have been expressed as picomoles of [125I]-αBTX binding sites 
precipitated per milliliter of serum ± SE. Data have been the result of three 
independent experiments. 
3.6 Statistical analysis 
 
All values have been expressed as means ± SE. Statistical analysis has been 
performed using Student‘s t test for two-group analysis or one-way ANOVA for 
multiple group comparisons (GraphPad Prism, CA). Statistical significance has 
been set at p<0.05 (*), p<0.01 (**), p<0.001 (***). 
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Chapter 4 – Results 
 
4.1 Effect of PIX on active cell proliferation in vitro 
 
We studied the effect of PIX on cell proliferation in vitro to evaluate the 
pharmacologic profile of the drug. For this purpose, we selected different cell 
subpopulations, characterized by different proliferative responses, stimulated with 
specific or aspecific antigen and concurrently exposed to a logarithmic range of 
PIX (0.1 pM - 1 µM) or vehicle (PBS), obtaining dose-response curves (Figure 4.1 
and 4.2). 
 
Figure 4.1 In vitro evaluation of PIX dose-response curves, on a R97-116 specific T cell line (Panel A), LNCs 
(Panel C) and SPNs (Panel E) from R97-116 immunized primed rats, stimulated with R97-116 (5 µg/ml, black 
circle) and ConA (2 µg/ml, white circle) in presence of a logarithmic range of PIX (0.1 pM-1 µM). Panel B, D 
and F represented the basal proliferation of cells in presence of R97-116 (5 µg/ml, black bar) and ConA (2 
µg/ml, white bar), exposed to vehicle (PBS). The lymphoid cells were stimulated with specific and aspecific 
antigens and exposed to PIX or vehicle  for three days of culture, then 0.5 µCi of [
3
H] thymidine was added for 
a further 18h. Data were expressed as a PIX mean IC50 pM ± SE, as a  result of at least three independent 
experiments. Data for basal proliferations were expressed as mean cpm ± SE, from triplicate wells for each 
conditions. 
As shown in Figure 4.1 – Panel A, PIX mean IC50 ± SE pM was 5.4 ± 1.4 pM and 
6.7 ± 1.2 pM in a rat CD4+ T cell line specific for the immunodominant peptide 
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R97–116 stimulated with ConA (2 µg/ml, aspecific mitogen) or R97-116 (5 µg/ml, 
specific antigen) respectively and exposed to PIX (0.1 pM – 1 µM). The Panel B 
showed the proliferation of the T cell line exposed to PBS and stimulated with the 
same antigens (mean cpm ± SE: CONA 39808 ± 6590 cpm; R97-116 43105 ± 
3043 cpm).  
Then we investigated the effect of PIX on mixed cell populations from immunized 
rats, HD rats and healthy human donors, with different percentage of cells in active 
proliferations, to delineate a diverse pharmacologic profile of the drug.  
LNCs and SPNs, derived from primed rats immunized with R97-116 (Figure 4.1 – 
Panel C and E), were stimulated with ConA (2 µg/ml) or antigen of immunization 
(R97-116, 5 µg/ml) and exposed simultaneously to PIX at the same concentrations 
previously described. The LNCs PIX mean IC50 ± SE pM resulted: ConA 25.7 ± 1.4 
pM, R97-116 63.3 ± 1.2 pM (Figure 4.1 - Panel C), while the SPNs PIX mean IC50 
± SE pM was: ConA 37.4 ± 1.2 pM; R97-116 54.3 ± 1.2 pM (Figure 4.1 - Panel E). 
The proliferation of both LNCs and SPNs (Figure 4.1 - Panel D and F) after 
exposure to the antigens and vehicle was: ConA 25808 ± 1505 cpm and R97-116 
14365 ±1209 cpm for LNCs, ConA 14055 ± 2986 cpm and R97-116 2376 ± 675 
cpm for SPNs.  
 
Figure 4.2 In vitro evaluation of PIX dose-response curves, on SPNs from HD rats (Panel A) and on PBMCs 
from healthy human donors  (Panel C) stimulated with ConA (2 µg/ml) and PHA (10 µg/ml) respectively, in 
presence of a logarithmic range of PIX (0.1 pM-1 µM). Panel B and D  represent the basal proliferation of cells 
in presence of ConA (2 µg/ml) and PHA (10 µg/ml) respectively, in presence of vehicle (PBS). The lymphoid 
cells were stimulated with aspecific antigens and exposed to PIX or vehicle for three days of culture, then 0.5 
µCi of [
3
H] thymidine was added for a further 18h. Data were expressed as a PIX mean IC50 pM ± SE, as a  
result of at least three independent experiments. Data for basal proliferations were expressed as mean cpm ± 
SE, from triplicate wells for each conditions. 
We considered the effect of the drug on lymphoid cells of HD rats (SPNs) and HD 
human donors (PBMCs), stimulated with aspecific mytogens (ConA, 2 µg/ml and 
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PHA, 10 µg/ml respectively) and exposed to PIX (0.1 pM - 1 µM, Figure 4.2 – 
Panel A and C). PIX effect resulted decreased compared to the previous 
experiments, since SPNs PIX mean IC50 ± SE pM resulted 679.5 ± 2.6 pM, and 
PBMCs PIX mean IC50 ± SE pM was equal to 3362.0 ± 1.5 pM. The proliferation of 
both cell subpopulations after exposure of aspecific mytogen and vehicle was 
equal to: mean cpm ± SE, 104623 ± 3595 cpm and 39572 ± 3094 cpm 
respectively (Figure 4.2 – Panel B and D). 
Furthermore for all the conditions studied we observed the complete suppression 
of proliferative response at the nM range, except for SPNs from HD rats and 
PBMCs from human healthy donors in which this was reached in µM range.  
4.2 PIX toxicity on MPCs differentiation in vitro 
 
We evaluated the in vitro toxic effect of PIX on the differentiations of bone marrow 
derived myeloid precursors cells (MPCs) from HD rats in iDCs. 
 
Figure 4.3 Panel A – Time course of in vitro toxic effect: MPCs were differentiated in iDCs, by adding 
GMCFS (5 ng/ml) and IL4 (5 ng/ml) to the growth medium and then exposed to vehicle (PBS) or PIX 
(0.1nM, 1nM, 10nM, 10 µM) at the time points 0 and 3 of cell differentiation. At the end of the 
experiments (t=7) cell numbers were counted by trypan blue exclusion. Panel B – Evaluation of iDCs 
viability at t=7 as the ratio between living cells and total cell counts (living and dead cells). The data 
were expressed as means viability % ± SE of three independent experiments. * p<0.05; *** p<0.001.  
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Rat MPCs were treated with PBS or PIX (0.1nM, 1nM, 10nM, 10 µM) at the time 
points 0 (t=0) and 3 (t=3) of differentiation in iDC (Figure 4.3 – Panel A). At the end 
of the experiments (t=7) cell numbers were counted by trypan blue exclusion and 
cell viability was evaluated as the ratio between living cells and total cell counts 
(living and dead cells). We considered as toxic effect a reduction in the cell viability 
≤ 50%. The iDCs viability % ± SE at time point 7 resulted: PIX 0.1nM t=3 71.0 ± 
0.5 %; t=0 64.5 ± 21.5 %; PIX 1 nM t=3 55.5 ± 15.5 %; t=0 33.0 ± 11.0 %; PIX 10 
nM t=3 13.0 ± 4.0 %; t=0 ALL DEAD %; PIX 10 µM t=3 ALL DEAD %; t=0 ALL 
DEAD %; vehicle t=7 92.0 ± 4.9 % (Figure 4.3 – Panel B). 
The toxic effect of PIX can be observed at the concentration 1 nM at day 7, 
moreover the total cell death was observed at PIX concentrations ≥ 10nM. 
4.3 PIX in TAChR-immunized primed rats 
 
Since PIX demonstrated in vitro a pharmacologic effect at picomolar 
concentrations and a significant toxic effect at nanomolar range, we investigated in 
vivo the effect of lower PIX dosage compared to that previously described [1]. 
We treated the TAChR-immunized rats 24 h p.i. with three different PIX dosages, 
chosen on the basis of the LD10: 16.25 mg/Kg (1/4 of PIX LD10; 16.25x1) as a 
positive control [1], 8.12 mg/Kg (8.12x1) equal to 1/8 of PIX LD10, and 4.06 mg/Kg 
(4.06x1) equal to 1/16 of PIX LD10. Negative control was represented by injection 
i.v. of a sterile saline solution (0.9% NaCl; vehicle). Healthy rats were also treated 
with 16.25 mg/Kg of PIX (HD/PIX) or vehicle (0.9% NaCl; HD) to evaluate the 
effect of PIX on LNCs in physiological conditions (Figure 4.4 – Panel A). 
Ten days p.i. LNCs were aseptically removed from all the treated rats, processed 
in a single cell suspensions and counted by trypan blue exclusion. As shown in 
Figure 4.4 – Panel B, the LNCs number from TAChR-immunized PIX treated rats 
was significantly decreased compared to vehicle treated rats. The number of total 
live cell count ± SE for each treatment was: 16.25x1 35.7x106 ± 3.6 live cells, 
8.12x1 56.7x106 ± 5.8 live cells, 4.06x1 45.3x106 ± 18.9 live cells; vehicle 
176.7x106 ± 29.9 live cells; p<0.05; while there was not any effect on the number 
of total live cell count in HD/PIX (6.1x106 ± 1.3 live cells) compared to HD controls 
(6.9x106 ± 0.9 live cells). 
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LNCs from TAChR-immunized rats were stimulated ex vivo with the antigen of 
immunization (TAChR 0.25 and 1.25 μg/ml) and ConA (2 μg/ml), as positive 
control. We evaluated the LNCs proliferation responses, normalizing the cpm data 
obtained for each PIX group versus vehicle and expressing the values as 
percentage: TAChR 0.25 μg/ml (proliferation responses % ± SE: 16.25x1 1.6 ± 
0.1%, 8.12x1 9.9 ± 1.4%, 4.06x1 5.1 ± 1.8%), TAChR 1.25 μg/ml (proliferation 
responses % ± SE: 16.25x1 5.6 ± 2.5%, 8.12x1 6.7 ± 2.0%, 4.06x1 7.0 ±2.4%) 
(Figure 4.4 – Panel D and E). ConA proliferative responses were not affected by 
PIX treatments (Figure 4.4 – Panel C).  
 
Figure 4.4 Effect of PIX on proliferative responses of LNCs from primed TAChR-immunized Lewis rats, 
treated i.v. with a single dose of PIX (16.25x1, 8.12x1, 4.06x1, n = 4 for each group) and vehicle-treated rats 
(n = 4) 24 hours p.i. (Panel A). Ten days p.i. popliteal and inguinal LNCs were aseptically removed and 
processed into a single-cell suspension. LNCs number were counted by trypan blue exclusion (Panel B). 
LNCs were stimulated ex vivo with ConA (2 µg/ml – Panel C) and TAChR (0.25µ g/ml and 1.25 µg/ml- Panel D 
and E). After 3 days of culture, 0.5 µCi of [
3
H]thymidine was added for a further 18 h. Data were expressed as 
mean proliferation percentage normalized to vehicle ± SE (triplicate wells from two independent experiments). 
The cpm values ± SE for control wells (medium alone) were: 16.25x1 273 ± 65 cpm, 8.12x1 430 ± 121 cpm, 
4.06x1 449 ± 172 cpm; for vehicle group 626 ± 60 cpm. *, p<0.05; **, p<0.01; ***, p<0.001.  
All dosages of PIX in TAChR-immunized rats led to a decreased LNCs antigen 
specific proliferation after exposure to both concentrations of TAChR, correlating 
with a decrease in total live cell count in LNCs.  
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4.4 Comparison of PIX therapeutic schedules in EAMG 
 
Previous results on TAChR-immunized primed rats demonstrated the effect of 
lower PIX dosages on antigen specific T cell proliferation responses, thus we 
focalized on EAMG therapeutic treatments with different PIX administrations 
(Table 4.1), decreasing the cumulative dosage at 24.36 mg/Kg or preserving it 
(48.75 mg/Kg) [1]. 
As shown in Figure 4.5 (Panel A and B) two PIX treatments were used for a 
cumulative dosage of 48.75 mg/Kg: 1) PIX 16.25 mg/Kg (16.25x3) q14dx3 as 
positive control [1]; 2) PIX 8.12 mg/Kg (8.12x6), q7dx6. Negative controls were 
represented to EAMG rats treated with sterile saline solution (0.9% NaCl, vehicle). 
EAMG clinical evaluations in PIX treated rats were significantly ameliorate 
compared to vehicle: mean of body weight ± SE 8.12x6 215 ± 8.5 g; 16.25x3 215 
± 9.9 g; vehicle 164 ± 4.2 g; p<0.05; mean of clinical score (arbitrary units, a.u.) ± 
SE 8.12x6 0 ± 0.1 a.u.; 16.25x3 1 ± 0.2 a.u.; vehicle 3 ± 0.2 a.u.  
Both of PIX treatments demonstrated an effective modulation of symptoms in 
EAMG model, but the posology equal to 8.12x6 determined an improved clinical 
score at the end of experiments (11 weeks p.i.) with a significative decrease 
compared to the positive control 16.25x3. 
 
Group # Posology Administration Cumulative Dosage 
16.25x3 3 q14dx3 16.25 mg/Kg 48.75 mg/Kg 
8.12x6 6 q7dx6 8.12 mg/Kg 48.75 mg/Kg 
8.12x3 6 q14dx3 8.12 mg/Kg 24.36 mg/Kg 
4.06x6 6 q7dx6 4.06 mg/Kg 24.36 mg/Kg 
Vehicle 7 q7dx6 0.9% NaCl - 
HD/PIX 3 q14dx3 16.25 mg/Kg 48.75 mg/Kg 
HD 3 q14dx3 0.9% NaCl - 
 
Table 4.1 Schedule of in vivo therapeutic treatments. Female Lewis rats, immunized with 
TAChR/CFA, were treated 4 weeks p.i with PIX (i.v.) according different administrations: a 
cumulative dosage of 48.75 mg/Kg and a decreased dosage of 24.36 mg/Kg, both with three 
times every 14 days (q14dx3) and once a week for six times (q7dx6). Vehicle and PIX 16.25 
mg/Kg q14dx3 (16.25x3) represented negative and positive control respectively. HD rats were 
administered with PIX (16.25 mg/Kg) or vehicle at the posology q14dx3. 
Concurrently we performed tests on body weight of healthy rats treated with PIX 
16.25mg/Kg (q14dx3; HD/PIX), compared with HD controls, in order to assess a 
decrease of this parameter as possible side effect. The data indicated that PIX 
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treatment did not affect the body weight of HD/PIX compared to HD controls 
(mean body weight ± SE: HD/PIX 243 ± 8.7 g, HD 232 ± 3.1 g). 
 
Figure 4.5 Comparison of therapeutic PIX treatments with a cumulative dosage of drug equal to 48.75mg/Kg 
on EAMG rats. Body weight (Panel A) and clinical score (Panel B) were recorded three times a week for 11 
weeks. Rats were randomly assigned to PIX group (n=6, filled diamonds) or remained in vehicle group (n=7, 
open diamonds) 4 weeks p.i. with TAChR/CFA. The protocol 16.25x3 was used as positive control (n=3) [1]. 
Vehicle group received sterile saline solution (n=7, negative control). The arrow indicates the first PIX injection 
(i.v.) for each protocol. Data were the result of two different experiments. Each PIX schedule was followed as 
indicated in Table 4.1. * p < 0.05 compared to vehicle. 
 
Since the cumulative dosage of 48.75 mg/Kg was effective on EMAG model, we 
investigated in vivo also the effect of a lower dosage of PIX and therefore we 
decreased the cumulative dosage of PIX to 24.36 mg/Kg, preserving PIX 
treatment 8.12 mg/Kg (8.12x6, q7dx6) as positive control and vehicle as negative 
control (Table 4.1).  
The two administrations of PIX 4.06 mg/Kg (4.06x6), q7dx6 and PIX 8.12 mg/Kg 
(8.12x3), q14dx3, both characterized by a cumulative dosage of 24.36 mg/Kg, 
resulted ineffective on improving EAMG, as at the end of the treatments (11 wk 
p.i.) the values related to body weight and clinical score were not modified 
compared to vehicle: mean of body weight ± SE: 4.06x6 164 ± 17.5 g; 8.12x3 133 
± 1.2 g; 8.12x6 215 ± 8.5 g; vehicle 164 ± 4.2 g; mean clinical score ± SE: 4.06x6 
3 ± 0.7 a.u.; 8.12x3 3.0 ± 0.9 a.u.; 8.12x6 0 ± 0.1 a.u.; vehicle 3 ± 0.2 a.u. (Figure 
4.6 - Panel A and B). 
Therefore only the schedules with PIX cumulative dosage 48.75 mg/Kg modulated 
the classical monitoring parameters of EAMG, resulting able to ameliorate the 
disease. Then these data underlined the importance of PIX cumulative dosage for 
a better efficacy of the drug in EAMG.  
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Figure 4.6 Comparison of therapeutic PIX treatments with a cumulative dosage of drug equal to 24.36 mg/Kg 
on EAMG rats. Body weight (Panel A) and clinical score (Panel B ) were recorded three times a week for 11 
weeks. Rats were randomly assigned to PIX group (n=6, filled diamonds) or remained in vehicle group (n=7, 
open diamonds) 4 weeks p.i. with TAChR/CFA. The protocol 8.12x6 was used as positive control (n=6). 
Vehicle group received sterile saline solution, as negative control. The arrow indicate the first PIX injection 
(i.v.) for each protocol. Data were the result of two different experiments. Each PIX schedule was followed as 
indicated in Table 4.1. * p < 0.05 compared to vehicle. 
4.5 Effect of PIX treatments on lymphoid cells  
 
At the end of the experiments (11 weeks p.i.), LNCs and MPCs were aseptically 
removed from vehicle, PIX-treated and HD rats, processed in a single cell 
suspension, and counted by trypan blue exclusion, evaluating the effect of PIX on 
LNCs and MPCs, two cell subpopulations with pathological and physiological 
implications respectively (Figure 4.7 - Panel A and B).  
PIX treatments at both cumulative dosage (48.75-24.36 mg/Kg) were able to affect 
the LNCs number: total live cell count ± SE: 16.25x3 13.0x106 ± 2.3 live cells, 
8.12x6 14.0x106 ± 3.8 live cells, 4.06x6 28.2x106 ± 3.0 live cells; 8.12x3 33.5x106 
± 8.9 live cells, vehicle 168.2x106 ± 19.7 live cells; p<0.05). LNCs cell count from 
HD/PIX (7.1x106 ± 4.1 live cells) and HD controls (6.9x106 ± 0.9 live cells) were 
not significantly different (Figure 4.7 - Panel A).  
Data on in vivo PIX myelotoxic effect (Figure 4.7 - Panel B) demonstrated that the 
number of MPCs from bone marrow were not impaired by TAChR-immunization 
compared to HD rats (total live cell count ± SE: vehicle 27.4 x106 ± 4.3 live cells; 
HD 32.9x106 ± 2.3 live cells) while the administration of PIX at the cumulative 
dosage 48.74 mg/Kg caused a significative decrease in this cell compartment 
compared to HD rats: total live cell count ± SE: 16.25x3 11.7 x106 ± 0.7 live cells; 
8.12x6 15.6x106 ± 1.5 live cells; HD/PIX 9.6x106 ± 2.6 live cells). Conversely the 
cumulative dosage of 24.36mg/Kg kept the level of cell subset unchanged 
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compared to HD controls (total live cell count ± SE: 4.06x3 31.2 x106 ± 10.6 live 
cells; 8.12x3 23.5x106 ± 3.1live cells).  
 
Figure 4.7 Popliteal/inguinal lymph nodes, such as myeloid precursor cells from bone marrow, were 
aseptically removed at the end of experiments from HD, vehicle and PIX treated rats and processed into 
single-cell suspensions. Cells were counted by trypan blue staining. Total live cell numbers of LNCs (Panel A) 
and MPCs (Panel B) were reported as mean ± SE from HD/PIX (n=3), HD controls (n= 3), vehicle-treated 
EAMG rats (n=7), and PIX treated EAMG rats (n=6 for each group), 16.25x3 (n=3), 8.12x6, 4.06x6 and 
8.12x3. Data were the result of two different independent experiments. * p<0.05; *** p<0.001 compared to HD 
controls. $ p<0.05 indicate the significant difference between  the protocols 16.25x3 and 8.12x6 
Thus we evaluated the effect of in vivo PIX treatments in EAMG rats on LNCs 
proliferative responses. LNCs from TAChR-immunized rats were stimulated ex 
vivo with the antigen of immunization (TAChR 0.25 and 1.25 μg/ml). We evaluated 
the LNCs proliferation responses, normalizing the cpm data obtained for each PIX 
group versus vehicle and expressing the values as percentage: TAChR 0.25 μg/ml 
(proliferative response % ± SE: 16.25x3 0.2 ± 0.01 % , 8.12x6 4 ± 2.2 %, 4.06x6 
3.4 ± 0.9 %, 8.12x3 16.4 ± 10.3 %), TAChR 1.25 μg/ml (proliferative response ± 
SE: 16.25x3 0.1 ± 0.01 % , 8.12x6 5.7 ± 3.4 %, 4.06x6 3.7 ± 2.3 %, 8.12x3 10.7 ± 
6.4 %), compared with the proliferative response observed in vehicle (TAChR 0.25 
μg/ml, proliferative response ± SE: 100.0 ± 4.3 %; TAChR 1.25 μg/ml, proliferative 
response ± SE:  100.0 ± 20.2 %, Figure 4.8, Panel A and B). PIX affected also 
ConA (2 g/ml – positive control) induced LNCs responses: proliferative response ± 
SE: 16.25x3 16.6 ± 0.8 % , 8.12x6  14.8 ± 1.4 %, 4.06x6 12.5 ± 0.9 %, 8.12x3 21.2 
± 4.3 %; vehicle 100.0 ± 4.5 %, p<0.01 (data not shown). 
All the treatments tested resulted able to interfere with specific TAChR proliferation 
responses, accordingly with a decrease in total live cell count on LNCs, 
demonstrating a possible pharmacological effect in vivo. The PIX myelotoxic effect 
instead was evident only for the cumulative dosage 48.75 mg/Kg, also in HD/PIX, 
but the schedule 8.12x6 resulted fewer toxic compared to the protocols 16.25x3 
administered both in EAMG and HD rats. 
 63 
 
 
Figure 4.8 LNCs were processed into a single-cell suspension and challenged in vitro with TAChR (0.25 – 
1.25 µg/ml) for 3 days, followed by [
3
H] thymidine for 18h. Data were expressed as mean proliferation 
percentage normalized to vehicle ± SE from triplicate wells. PIX treatments: 16.25x3 (n=3), 8.12x6 (n=6); 
4.06x6 (n=6); 8.06x3 (n=6). Vehicle group (n=7) was treated with sterile saline solution as placebo. Mean cpm 
±  SE for control wells (medium alone) were: 16.25x3 176 ± 57; 8.12x6 149 ± 31; 4.06x6 111 ± 23; 8.06x3 76 
± 12; vehicle 105±11. Data were the result of two different independent experiments. *, p<0.05; **, p<0.01; ***, 
p<0.001. 
4.6 Effect of PIX on IFNγ mRNA transcription level and 
Anti Rat-Abs titer 
 
We then tested the effect of PIX on mRNA IFNγ transcription levels, analyzing a 
population of lymphoid cells from spleen (SPNs). The spleen is a secondary 
lymphoid organ, such as lymph nodes, involved in production of Th1 cells in 
response to the antigen and involved in the autoimmune process. Total mRNA 
was extracted from SPNs of EAMG PIX treated rats with both cumulative dosages 
and vehicle. In parallel we evaluated also mRNA transcription level on SPNs from 
HD rats (n=3) in order to assess the IFNγ physiological level and correlate it with 
the effect of the PIX treatments.  
As shown in Figure 4.9 only the treatments with a cumulative dosage equal to 
48.75 mg/Kg were able to reduce IFNγ mRNA transcription levels compared to 
vehicle, with values close to HD rats (not significant difference when it was 
compared with HD controls). Instead IFNγ mRNA transcription levels in the PIX 
treatments with a cumulative dosage of 24.36 mg/Kg were unchanged compared 
to vehicle. IFNγ mRNA transcription levels for each group of treatments and HD 
controls were expressed as mean 2-ΔCtx100 ± SE: HD rats 0.0063 ± 0.0004%; 
vehicle 0.406 ± 0.099%; 16.25x3 0.018 ± 0.006% (p<0.001); 8.12x6 0.0215 ± 
0.005% (p<0.001); 4.06x6 0.0915 ± 0.0665%; 8.12x3 0.9690 ± 0.1060%. 
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Figure 4.9 IFNγ mRNA transcription levels evaluation by ex vivo Real-Time qPCR 
analysis of SPNs from HD (n=3), EAMG rats treated with PIX (n = 6 for each group) 
or vehicle(n=7). Transcript levels were calculated according to the 2
-ΔCt
 method; β 
actin was used as endogenous control to normalize mRNA amount. Bars 
represented means 2
-ΔCt
x100 ± SE. Data were the result of three independent 
experiments. *** p < 0.001 compared to vehicle.  
We then evaluated the effect of PIX treatments on the level of pathogenic Abs 
(IgG type) against Rat-AChR in the sera of PIX and vehicle treated rats. Also in 
this case the effect of PIX resulted cumulative dosage dependent (Figure 4.10).  
 
Figure 4.10 Anti-Rat AChR Abs titer were measured by conventional 
radioimmunoprecipitation assay in serum samples collected at the end of the 
experiments. Circulating anti-rat AChR Abs (IgG type) have been evaluated in 
individual samples in duplicate and were expressed as mean ± SE (pmol/ml) for 
treatment groups: vehicle treated EAMG rats (n=7) and therapeutic PIX schedules 
in EAMG rats, 16.25x3 (n=3) 8.12x6 (n=6), 4.06x6 (n=6) and 8.12x3(n=6). PIX 
16.25x3 was used as positive control, while HD rats as negative control: mean 
pmol serum/ml ± SE was equal to 0.31 ± 0.005 pmol/ml. Data were the result of two 
independent experiments.  ** p < 0.01. 
EAMG rats treated with PIX at the cumulative dosage of 48.75 mg/Kg showed a 
significative decrease in the Abs titer (mean titer pmol/ml sera ± SE: 16.25x3 2.4 ± 
0.3 pmol/ml, 8.12x6 6.3 ± 4.9 pmol/ml) compared to vehicle group (mean titer 
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pmol/ml sera ± SE: 73.4 ± 5.7 pmol/ml). Whereas animals treated with PIX at the 
cumulative dosage 24.36 mg/Kg showed no improvement (mean titer pmol/ml sera 
± SE: 4.06x6 55.1 ± 0.7 pmol/ml, 8.12x3 53.6 ± 8.7 pmol/ml). The reduction 
percentage of Rat AChR Abs titer for each group compared to vehicle was: 
16.25x6 96.8 %; 8.12x3 91.5 %; 4.06x6 24.9 %; 8.12x3 26.9 %.  
Only the treatments with the cumulative dosage 48.75 mg/Kg were able to 
reduced mRNA IFNγ transcription levels on SPNs, accordingly with a decrease on 
Anti-Rat Abs titer in the sera of treated rats, that correlated at the end with an 
improved on the clinical parameters of EAMG. On the contrary the cumulative 
dosage 24.36 mg/Kg resulted not sufficient to interfere with levels of IFNγ with a 
consequent production of Anti-Rat Abs and an exacerbation of the disease. 
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Chapter 5 – Discussion 
 
Therapeutic options for MG include corticosteroids and immunosuppressive drugs, 
pharmacological agents exerting a nonspecific generalized immune dysfunction 
[33]. These drugs are effective in a large proportion of patients. However, the 
clinical response to conventional treatments is unsatisfactory in some patients, or 
the severity of side effects may represent a limiting factor to the prolonged drug-
administration. In this regard, new potent but well-tolerated immunosuppressive 
drugs are needed for MG [1]. 
Indeed, new immunosuppressants are under investigation in clinical trials to 
assess their efficacy on human autoimmune diseases. Mitoxantrone is a synthetic 
anthracenedione antineoplastic compound, initially used for the treatment of adult 
acute myeloid leukemia; more recently this compound has been approved by FDA 
for use in specific forms of multiple sclerosis [178]. MTX has a broad range of 
effects on the immune system because it is able to suppress proliferation of T 
cells, B cells, macrophages, and impairs antigen presentation mainly by the 
induction of APCs apoptosis. Moreover, experimental studies showed that MTX 
suppresses B cell function, Ab production, and reduces the release of 
proinflammatory cytokines. 
Such a wide range of effects might be useful to control the immune attack in 
patients with MG, a T cell-dependent, B cell-mediated autoimmune disease. 
However, the major limitation to the use of MTX in MG as well as in other 
autoimmune disorders is its cardiotoxicity, resulting in congestive heart failure, with 
an increased risk with cumulative doses above 100 mg/m2 [179]. 
PIX, structurally related to MTX, has similar mechanism of actions, same 
antineoplastic activity but presents a lower cardiotoxicity. The effect of PIX has 
been evaluated in the animal model of multiple sclerosis (EAE). Experimental 
studies showed that PIX can prevent the onset of EAE in SJL mice but is also able 
to modify the course of the disease in rats once the disease is established [148, 
171]. These effects have been attributed to the long-lasting effect of PIX on 
several lymphocyte subpopulations and on Ag presentation. The observed effects 
were dose-dependent, and no signs of cardiotoxicity compared with MTX were 
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observed. Interestingly, the B cell response to myelin basic protein was also 
inhibited, providing a further mechanism of action to explain the reduced 
demyelination observed in treated animals. 
The effect of PIX has been also investigated in EAMG, the animal model of MG. 
Ubiali et al. demonstrated that PIX was able to ameliorate EAMG both in the 
preventive and therapeutic treatments, when administered i.v. at the dose 16.25 
mg/Kg (1/4 of the LD10 q7dx3), with a cumulative dosage of 48.75 mg/Kg [1]. 
In the present study we investigated whether reduced PIX cumulative dosages or 
modified schedules of treatments were still able to ameliorate EAMG. 
We first addressed the issue of PIX effect on the in vitro proliferative response of 
lymphoid cells, in order to determine the pharmacologic properties of the drug in 
presence of different cells subpopulations, characterized by different proliferative 
responses. For this purpose, by dose-response curves we demonstrated that PIX 
(0.1 pM - 1 µM) inhibits lymphoid cell responses in a dose dependent manner. As 
shown in Figure 4.1 and 4.2, the calculated IC50 values were specific for the 
different cell subpopulations studied: IC50 was 5.4 pM for ConA-stimulated CD4+ 
Tcell line, 6.7 pM for R97-116-stimulated CD4+ Tcell line; 25.7 pM for ConA-
stimulated LNCs, 63.3 pM for AChR (R97-116) stimulated LNCs; 37.4 pM ConA-
stimulated SPNs and 54.3 pM for AChR (R97-116) stimulated SPNs. Complete 
suppression of proliferative responses was achieved with nM PIX concentrations 
for cells in active proliferation such as the R97-116 T cell line or LNCs and SPNs 
from R97-116 primed rats (Figure 4.1), and with µM PIX concentrations for SPNs 
from HD rats and PBMCs from healthy human donors (Figure 4.2).  
Our data demonstrated that a lower concentration of PIX was sufficient to inhibit 
50% of maximal response of an antigen specific T cell line, represented by an 
homogeneous pool of cells (more than 90%) capable of producing a robust cell 
proliferation in response of the specific antigen, i.e. the R97-116 peptide. In mixed 
populations, such as LNCs and SPNs isolated from R97-116 primed rats, in which 
we estimated to have 20-40% of antigen-specific cells, or even in SPNs from HD 
rats and PBMCs from healthy human donors, the IC50 for PIX is found to be 
increased. Our in vitro experiments suggested that PIX efficacy is higher for T cells 
that are able to actively proliferate. 
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We also evaluated whether PIX might alter differentiation of bone marrow MPCs 
from HD rats (Figure 4.3) in immature dendritic cells. Our data demonstrated that 
PIX 1 nM was able to reduce cell viability below 50% at day 7 of the differentiation 
protocol when the drug is added to the cell culture medium at day=0. When PIX 
was used at 10 nM and 10 µM, the observed vitality was dramatically dropped 
down to 0%. 
Altogether our data on the in vitro pharmacological and toxicological effect of PIX 
demonstrated that PIX was able to exert a pharmacological effect when used in 
the picomolar range, compared with a toxic effect observed in the nanomolar 
range. Both of these in vitro aspects were relevant for the design of a different 
therapeutic schedules of in vivo treatments with PIX in the EAMG model. 
Next, we studied the ex vivo response of LNCs from TAChR immunized rats 
(Figure 4.4) treated 24 h p.i. with a single dose of PIX (16.25 mg/Kg x1, 8.12 
mg/Kg x1, 4.06 mg/Kg x1) or vehicle, and sacrificed after 10 days. All the 
conditions tested demonstrated that PIX was able to interfere with the 
immunocompetent cells, as assessed by a 70% reduction in total live cell count in 
PIX-treated TAChR immunized rats. These results correlated with a decrease 
(90%) of TAChR-specific proliferation from LNCs obtained from PIX treated rats 
compared to vehicle treated animals. In parallel we tested the effect of the higher 
PIX treatment (16.25 mg/Kg x1) in HD rats, in order to assess if PIX was able to 
interact with lymphoid cell compartment in physiological conditions: our data 
indicated that the drug had no effect on the number of total living cells. We 
speculated that PIX did not interfere in vivo with the pool of naïve T cells, 
physiologically present in LNCs, compared to the strong effect of the drug in 
AChR-primed rats, in which the immunization stimulated the active proliferation of 
pathogenic T CD4+ cells against TAChR. Furthermore we analyzed the effect of 
PIX treatment (16.25 mg/Kg x1) on HD rats immunized only with CFA, to 
investigate the eventual influence of PIX on antigens present in CFA, but the drug 
had no effect on total living cell count in this condition (data not shown).  
Our data demonstrated that also the lower PIX dosage (4.06 mg/Kg x1) was able 
to exert immunomodulating properties in vivo and allowed us to test new 
therapeutic schedules for EAMG treatment.  
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Furthermore, we investigated in vivo the effect of long term treatments with PIX in 
EAMG rats, with two cumulative dosage (48.75 mg/Kg, Figure 4.5, and 24.36 
mg/Kg, Figure 4.6), and by comparing different treatment protocols described in 
Table 4.1. The effect of a chronic administration of the drug has been also 
assessed in HD rats, by extending the treatment period to 6 weeks compared to 
the previous study (4 weeks) [1]. We initially assessed whether a difference can 
occur between the protocol 16.25 mg/Kg q14dx3 and q7dx6 [1]. Our preliminary 
data shown that both protocols were efficacy in EAMG modulation. According to 
these results, we selected the schedule 16.25x3 q14dx3 as positive control.  
The PIX cumulative dosage of 48.75 mg/Kg was able to modify the course of the 
disease, as shown by the positive trend of clinical scores in treated rats, and by 
the assessment of body weight. At week 7 a difference in the mean clinical score 
of PIX-treated rats compared to EAMG controls can be observed. At the end of 
experiment (week 11), animals that received PIX 8.12 mg/Kg x6 had a statistically 
different mean clinical score compared with the protocol 16.25 mg/Kg x3 (p<0.05), 
with EAMG clinical score similar to normal control animals. We speculated that this 
effect could be related to the PIX pharmacokinetic profile in the schedule 8.12x6. 
In this protocol, PIX administration overlaps well with its clearance (8 days), thus 
allowing the achievement of a systemic steady-state, with the consequent 
improvement of the efficacy of this treatment compared to 16.25x3 schedule.  
As regard to the PIX cumulative dosage corresponding to 24.36 mg/Kg, both of 
schedules (8.12x3 mg/Kg and 4.06x6 mg/Kg) compared to 8.12x6, as it proved to 
be the most effective, did not present any modifications in EAMG clinical 
manifestations (clinical score and body weight) compared to vehicle, but caused a 
marked inhibition of TAChR-specific proliferation from LNCs obtained from PIX 
treated rats compared to vehicle treated animals (Figure 4.8, Panel A and B). In 
parallel we demonstrated that these data were correlated to a reduction of 80% in 
the number of total live cell counts in the same organ (Figure 4.7, Panel A).  
We also evaluated the myelotoxicity of drug in myeloid precursors cells, derived 
from PIX-treated rats with different schedules, counting total live cell numbers 
(Table 4.1). We observed that TAChR-immunization did not affect the viability of 
myeloid precursor cells compared to HD controls and that PIX cumulative dosage 
of 48.75 mg/Kg (16.25x3 mg/Kg and 8.12x6 mg/Kg) caused myelotoxicity both in 
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EAMG/PIX and HD/PIX rats compared to HD controls (Figure 4.7, Panel B). 
Indeed treatment of PIX 8.12x6 mg/Kg resulted less toxic (48%) than the protocol 
of 16.25x3 mg/Kg (60%). On the contrary the cumulative dosage of 24.75 mg/Kg 
did not interfere on cell viability compared to HD controls.  
Next we evaluated in SPNs the mRNA transcription level of IFNγ, an important 
cytokine involved in the development of EAMG, produced by Th1 cells and 
activating Abs production from B cells (Figure 4.9). We studied mRNA 
transcription level in splenocytes, since spleen is a secondary lymphoid organ, 
involved in production of Th1 cells in response to the antigen and involved in the 
autoimmune process. PIX cumulative dosage of 48.75 mg/Kg was able to 
significantly decrease IFNγ mRNA transcription level in both schedules compared 
to the vehicle. On the contrary, treatments with cumulative dosage of 24.36 mg/Kg 
were not effective in decreasing these values. 
These data were correlated with the specific Anti Rat AChR Abs titers detected in 
the sera of PIX and vehicle EAMG rats (Figure 4.10). In fact the decrease of IFNγ 
mRNA transcription level, found in PIX treated EAMG rats (cumulative dosage of 
48.75 mg/Kg), corresponded to a reduction of 90% in Abs titer compared to 
vehicle. Although we observed an effect on TAChR specific proliferation of LNCs, 
treatments with cumulative dosage of 24.36 mg/Kg resulted ineffective to inhibit 
the production of pathogenic Anti Rat AChR Abs (Figure 4.10). 
In conclusion, our data demonstrated that only PIX schedules with cumulative 
dosage of 48.75 mg/Kg, were able to ameliorate ongoing EAMG; in particular, the 
treatment with 8.12x6 mg/Kg resulted more effective due to its pharmacokinetic 
profile. The cumulative dosage of 24.36 mg/Kg resulted inefficacious to modulate 
EAMG because it didn‘t reach the systemic effective dose in rats. 
A further important feature of PIX treatment is its administration schedule once a 
week, thus limiting the severity of side effects. On the basis of our results we 
propose PIX as a promising immunomodulatory drug for the design of a clinical 
study in MG patients non-responsive to common therapies.
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